<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head>

<meta charset="utf-8">
<meta name="generator" content="quarto-1.4.550">

<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">

<meta name="author" content="G. Bisaccia">

<title>G. Bisaccia, MD, PhD - VALUE OF QUANTITATIVE STRESS PERFUSION CARDIOVASCULAR MAGNETIC RESONANCE IN THE LONG-TERM ASSESSMENT OF CARDIAC TRANSPLANTATION RECIPIENTS</title>
<style>
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
div.columns{display: flex; gap: min(4vw, 1.5em);}
div.column{flex: auto; overflow-x: auto;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
ul.task-list li input[type="checkbox"] {
  width: 0.8em;
  margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
  vertical-align: middle;
}
/* CSS for citations */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
  margin-bottom: 0em;
}
.hanging-indent div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}</style>


<script src="site_libs/quarto-nav/quarto-nav.js"></script>
<script src="site_libs/quarto-nav/headroom.min.js"></script>
<script src="site_libs/clipboard/clipboard.min.js"></script>
<script src="site_libs/quarto-search/autocomplete.umd.js"></script>
<script src="site_libs/quarto-search/fuse.min.js"></script>
<script src="site_libs/quarto-search/quarto-search.js"></script>
<meta name="quarto:offset" content="./">
<script src="site_libs/quarto-html/quarto.js"></script>
<script src="site_libs/quarto-html/popper.min.js"></script>
<script src="site_libs/quarto-html/tippy.umd.min.js"></script>
<script src="site_libs/quarto-html/anchor.min.js"></script>
<link href="site_libs/quarto-html/tippy.css" rel="stylesheet">
<link href="site_libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<script src="site_libs/bootstrap/bootstrap.min.js"></script>
<link href="site_libs/bootstrap/bootstrap-icons.css" rel="stylesheet">
<link href="site_libs/bootstrap/bootstrap.min.css" rel="stylesheet" id="quarto-bootstrap" data-mode="light">
<script id="quarto-search-options" type="application/json">{
  "location": "navbar",
  "copy-button": false,
  "collapse-after": 3,
  "panel-placement": "end",
  "type": "overlay",
  "limit": 50,
  "keyboard-shortcut": [
    "f",
    "/",
    "s"
  ],
  "show-item-context": false,
  "language": {
    "search-no-results-text": "No results",
    "search-matching-documents-text": "matching documents",
    "search-copy-link-title": "Copy link to search",
    "search-hide-matches-text": "Hide additional matches",
    "search-more-match-text": "more match in this document",
    "search-more-matches-text": "more matches in this document",
    "search-clear-button-title": "Clear",
    "search-text-placeholder": "",
    "search-detached-cancel-button-title": "Cancel",
    "search-submit-button-title": "Submit",
    "search-label": "Search"
  }
}</script>


<link rel="stylesheet" href="styles.css">
</head>

<body class="nav-fixed">

<div id="quarto-search-results"></div>
  <header id="quarto-header" class="headroom fixed-top">
    <nav class="navbar navbar-expand-lg " data-bs-theme="dark">
      <div class="navbar-container container-fluid">
      <div class="navbar-brand-container mx-auto">
    <a href="./index.html" class="navbar-brand navbar-brand-logo">
    <img src="./images/profile.jpg" alt="" class="navbar-logo">
    </a>
    <a class="navbar-brand" href="./index.html">
    <span class="navbar-title">G. Bisaccia, MD, PhD</span>
    </a>
  </div>
            <div id="quarto-search" class="" title="Search"></div>
          <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbarCollapse" aria-controls="navbarCollapse" aria-expanded="false" aria-label="Toggle navigation" onclick="if (window.quartoToggleHeadroom) { window.quartoToggleHeadroom(); }">
  <span class="navbar-toggler-icon"></span>
</button>
          <div class="collapse navbar-collapse" id="navbarCollapse">
            <ul class="navbar-nav navbar-nav-scroll me-auto">
  <li class="nav-item">
    <a class="nav-link" href="./index.html"> 
<span class="menu-text">Home</span></a>
  </li>  
  <li class="nav-item">
    <a class="nav-link" href="./about.html"> 
<span class="menu-text">About</span></a>
  </li>  
  <li class="nav-item">
    <a class="nav-link" href="./portfolio.html"> 
<span class="menu-text">Portfolio</span></a>
  </li>  
  <li class="nav-item">
    <a class="nav-link" href="./cv.html"> 
<span class="menu-text">CV</span></a>
  </li>  
  <li class="nav-item">
    <a class="nav-link" href="./publist.html"> 
<span class="menu-text">Publications</span></a>
  </li>  
</ul>
            <ul class="navbar-nav navbar-nav-scroll ms-auto">
  <li class="nav-item">
    <a class="nav-link" href="./md.html"> <i class="bi bi-mortarboard" role="img">
</i> 
<span class="menu-text">MD thesis</span></a>
  </li>  
  <li class="nav-item">
    <a class="nav-link active" href="./phd.html" aria-current="page"> <i class="bi bi-mortarboard-fill" role="img">
</i> 
<span class="menu-text">PhD thesis</span></a>
  </li>  
  <li class="nav-item compact">
    <a class="nav-link" href="https://github.com/giandomd"> <i class="bi bi-github" role="img">
</i> 
<span class="menu-text"></span></a>
  </li>  
  <li class="nav-item compact">
    <a class="nav-link" href="https://x.com/giandomd"> <i class="bi bi-twitter" role="img">
</i> 
<span class="menu-text"></span></a>
  </li>  
  <li class="nav-item compact">
    <a class="nav-link" href="https://linkedin.com/in/bisacciamd"> <i class="bi bi-linkedin" role="img">
</i> 
<span class="menu-text"></span></a>
  </li>  
</ul>
          </div> <!-- /navcollapse -->
          <div class="quarto-navbar-tools">
</div>
      </div> <!-- /container-fluid -->
    </nav>
</header>
<!-- content -->
<div id="quarto-content" class="quarto-container page-columns page-rows-contents page-layout-article page-navbar">
<!-- sidebar -->
<!-- margin-sidebar -->
    <div id="quarto-margin-sidebar" class="sidebar margin-sidebar">
        <nav id="TOC" role="doc-toc" class="toc-active">
    <h2 id="toc-title">On this page</h2>
   
  <ul>
  <li><a href="#abstract" id="toc-abstract" class="nav-link active" data-scroll-target="#abstract">Abstract</a></li>
  <li><a href="#outline" id="toc-outline" class="nav-link" data-scroll-target="#outline">Outline</a></li>
  <li><a href="#introduction" id="toc-introduction" class="nav-link" data-scroll-target="#introduction">Introduction</a>
  <ul class="collapse">
  <li><a href="#cardiac-transplantation" id="toc-cardiac-transplantation" class="nav-link" data-scroll-target="#cardiac-transplantation">Cardiac transplantation</a>
  <ul class="collapse">
  <li><a href="#complications-following-cardiac-transplantation" id="toc-complications-following-cardiac-transplantation" class="nav-link" data-scroll-target="#complications-following-cardiac-transplantation">Complications following cardiac transplantation</a></li>
  <li><a href="#cardiac-allograft-vasculopathy" id="toc-cardiac-allograft-vasculopathy" class="nav-link" data-scroll-target="#cardiac-allograft-vasculopathy">Cardiac allograft vasculopathy</a></li>
  </ul></li>
  <li><a href="#methods" id="toc-methods" class="nav-link" data-scroll-target="#methods">Methods</a>
  <ul class="collapse">
  <li><a href="#design" id="toc-design" class="nav-link" data-scroll-target="#design">Design</a></li>
  <li><a href="#study-cases" id="toc-study-cases" class="nav-link" data-scroll-target="#study-cases">Study cases</a></li>
  <li><a href="#procedures-and-tests" id="toc-procedures-and-tests" class="nav-link" data-scroll-target="#procedures-and-tests">Procedures and tests</a></li>
  <li><a href="#follow-up" id="toc-follow-up" class="nav-link" data-scroll-target="#follow-up">Follow-up</a></li>
  <li><a href="#data-collection" id="toc-data-collection" class="nav-link" data-scroll-target="#data-collection">Data collection</a></li>
  <li><a href="#statistics" id="toc-statistics" class="nav-link" data-scroll-target="#statistics">Statistics</a></li>
  </ul></li>
  <li><a href="#results" id="toc-results" class="nav-link" data-scroll-target="#results">Results</a>
  <ul class="collapse">
  <li><a href="#baseline-characteristics" id="toc-baseline-characteristics" class="nav-link" data-scroll-target="#baseline-characteristics">Baseline characteristics</a></li>
  <li><a href="#angiographic-findings" id="toc-angiographic-findings" class="nav-link" data-scroll-target="#angiographic-findings">Angiographic findings</a></li>
  <li><a href="#cmr-findings" id="toc-cmr-findings" class="nav-link" data-scroll-target="#cmr-findings">CMR findings</a></li>
  <li><a href="#stress-cmr-findings" id="toc-stress-cmr-findings" class="nav-link" data-scroll-target="#stress-cmr-findings">Stress CMR findings</a></li>
  <li><a href="#diagnostic-accuracy-1" id="toc-diagnostic-accuracy-1" class="nav-link" data-scroll-target="#diagnostic-accuracy-1">Diagnostic accuracy</a></li>
  <li><a href="#clinical-utility-1" id="toc-clinical-utility-1" class="nav-link" data-scroll-target="#clinical-utility-1">Clinical utility</a></li>
  <li><a href="#prognostic-yield-1" id="toc-prognostic-yield-1" class="nav-link" data-scroll-target="#prognostic-yield-1">Prognostic yield</a></li>
  </ul></li>
  <li><a href="#discussion" id="toc-discussion" class="nav-link" data-scroll-target="#discussion">Discussion</a></li>
  <li><a href="#limitations" id="toc-limitations" class="nav-link" data-scroll-target="#limitations">Limitations</a></li>
  <li><a href="#future-perspectives" id="toc-future-perspectives" class="nav-link" data-scroll-target="#future-perspectives">Future perspectives</a></li>
  <li><a href="#conclusion" id="toc-conclusion" class="nav-link" data-scroll-target="#conclusion">Conclusion</a></li>
  <li><a href="#references" id="toc-references" class="nav-link" data-scroll-target="#references">References</a></li>
  <li><a href="#appendix" id="toc-appendix" class="nav-link" data-scroll-target="#appendix">Appendix</a>
  <ul class="collapse">
  <li><a href="#statistical-software-and-packages" id="toc-statistical-software-and-packages" class="nav-link" data-scroll-target="#statistical-software-and-packages">Statistical software and packages</a></li>
  <li><a href="#supplemental-results" id="toc-supplemental-results" class="nav-link" data-scroll-target="#supplemental-results">Supplemental results</a></li>
  <li><a href="#supplemental-tables" id="toc-supplemental-tables" class="nav-link" data-scroll-target="#supplemental-tables">Supplemental tables</a></li>
  <li><a href="#supplemental-figures" id="toc-supplemental-figures" class="nav-link" data-scroll-target="#supplemental-figures">Supplemental figures</a></li>
  </ul></li>
  <li><a href="#list-of-publications" id="toc-list-of-publications" class="nav-link" data-scroll-target="#list-of-publications">List of publications</a></li>
  <li><a href="#license" id="toc-license" class="nav-link" data-scroll-target="#license">License</a></li>
  </ul></li>
  </ul>
</nav>
    </div>
<!-- main -->
<main class="content" id="quarto-document-content">

<header id="title-block-header" class="quarto-title-block default">
<div class="quarto-title">
<h1 class="title">VALUE OF QUANTITATIVE STRESS PERFUSION CARDIOVASCULAR MAGNETIC RESONANCE IN THE LONG-TERM ASSESSMENT OF CARDIAC TRANSPLANTATION RECIPIENTS</h1>
<p class="subtitle lead">PhD thesis, 2024</p>
</div>


<div class="quarto-title-meta-author">
  <div class="quarto-title-meta-heading">Author</div>
  <div class="quarto-title-meta-heading">Affiliation</div>
  
    <div class="quarto-title-meta-contents">
    <p class="author">G. Bisaccia, MD, PhD <a href="https://orcid.org/0000-0003-4606-3093" class="quarto-title-author-orcid"> <img src="data:image/png;base64,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"></a></p>
  </div>
  <div class="quarto-title-meta-contents">
        <p class="affiliation">
            Gabriele d’Annunzio University of Chieti and Pescara, Italy and Harefield Hospital, London, United Kingdom. PhD in Neuroscience and Imaging (XXXVII Cycle)
          </p>
      </div>
  </div>

<div class="quarto-title-meta">

      
  
    
  </div>
  


</header>


<p>Supervisors: Prof.&nbsp;Sabina Gallina MD, Prof.&nbsp;Chiara Bucciarelli-Ducci, MD, PhD, Prof.&nbsp;Fabrizio Ricci, MD, PhD, MSc</p>
<section id="abstract" class="level2">
<h2 class="anchored" data-anchor-id="abstract">Abstract</h2>
<p><strong>Background</strong>: Heart transplantation is the treatment of choice in select patients with advanced heart failure. Since its introduction in the early 1970s, it has delivered significant benefits in survival and quality of life of these patients. However, despite significant progress in the selection of patients, technical aspects of the procedures and long-term outcomes, HT recipients face a significant risk of future complications, namely graft rejection and cardiac allograft vasculopathy, which warrant regular invasive monitoring with cardiac catheterisation. Stress perfusion cardiac magnetic resonance imaging (stress CMR) is recommended in the international guidelines in class I in patients with known or suspected coronary artery disease, but its role in post-HT surveillance is yet to be established. We sought to assess the safety and feasibility profile, as well as the diagnostic and prognostic yield and the overall clinical utility of quantitative stress CMR in HT recipients referred for assessment of cardiac allograft vasculopathy (CAV).</p>
<p><strong>Methods</strong>: A retrospective study of all orthotopic HT recipients undergoing clinically indicated stress perfusion CMR with adenosine was conducted. The safety and feasibility profile was demonstrated by evaluating any adverse events during or immediately following adenosine infusion and the elicited change in haemodynamic parameters. The diagnostic endpoint was area under the curve (AUC) for angiography-defined graft vasculopathy. The utility endpoint was the net benefit purported by undergoing stress CMR as a gatekeeper to angiography at a prespecified threshold range (10-40%). The prognostic endpoint was time to occurrence of a major adverse cardiac event (unplanned cardiac hospitalization or death from any cause).</p>
<p><strong>Results</strong>: 60 HT recipients were identified having stress CMR and angiography. Prevalence of CAV was 30%. Adenosine stress CMR was safe with no serious adverse events noted. Myocardial perfusion reserve index had an AUC for significant CAV of 0.79, with sensitivity 85.7%, specificity 70.3%, positive predictive value of 52.2% and negative predictive value of 92.9% at a Youden threshold of 2.1. A total of 11 patients experienced MACE at a median follow-up of 1.8 years. Myocardial perfusion reserve index, along with stress MBF, was a significant risk predictor. As a gatekeeper to invasive testing, stress CMR with quantitative perfusion showed superior decisional performance than stress CMR alone, allowing as much as 39% of patients to properly avoid angiography.</p>
<p><strong>Conclusions</strong>: Stress CMR with quantitative perfusion showed excellent safety and feasibility in HT recipients, and superior accuracy, prognostic yield and decisional performance than stress CMR alone. These findings warrant prospective confirmation.</p>
</section>
<section id="outline" class="level2">
<h2 class="anchored" data-anchor-id="outline">Outline</h2>
<p>Stress cardiac magnetic resonance (CMR) perfusion imaging is recommended in international guidelines as class I in patients with known or suspected coronary artery disease <span class="citation" data-cites="RN1">(<a href="#ref-RN1" role="doc-biblioref">1</a>)</span>, and is a promising non-invasive technique for the detection of cardiac allograft vasculopathy (CAV) of cardiac transplantation recipients <span class="citation" data-cites="RN2">(<a href="#ref-RN2" role="doc-biblioref">2</a>)</span>. Yet, there are concerns regarding the use of vasodilators after heart transplantation <span class="citation" data-cites="RN3">(<a href="#ref-RN3" role="doc-biblioref">3</a>)</span>. Further, the clinical utility of stress CMR in cardiac transplantation recipients has not been formally investigated. Finally, the comparative diagnostic accuracy and prognostic yield of fully quantitative versus qualitative stress perfusion CMR in cardiac transplantation have not been previously established. Accordingly, we aimed to assess 1) the safety and feasibility profile, 2) the diagnostic and prognostic yield, and 3) overall clinical utility of adenosine stress CMR perfusion in HT recipients with suspected CAV. This thesis comprises three parts. In <em>chapter 1</em>, a literature review is presented on the contemporary use and outcomes of heart transplantation, and current strategies for quality optimisation in long-term CAV surveillance are briefly outlined. Results of a systematic review on use of stress CMR after heart transplantation are presented. In <em>chapters 2–3</em>, the methods and findings of the study are shown. In <em>chapters 4–6</em>, results are discussed and put into the broader context of research on post-transplantation surveillance; study limitations are addressed, and future developments proposed. Finally, the <em>Appendix</em> addresses some open queregarding the haemodynamic response to pharmacological vasodilation in the transplanted heart, and its implications for the measurement and clinical value of myocardial blood flow.</p>
</section>
<section id="introduction" class="level1">
<h1>Introduction</h1>
<section id="cardiac-transplantation" class="level2">
<h2 class="anchored" data-anchor-id="cardiac-transplantation">Cardiac transplantation</h2>
<p>Cardiac transplantation is the selected destination treatment in patients with advanced heart failure <span class="citation" data-cites="RN4">(<a href="#ref-RN4" role="doc-biblioref">4</a>)</span>. This procedure, introduced in the late 1960s and originally looked upon with skepticism and suspicion, offers unparalleled improvement in both prognosis and quality of life in patients with ongoing symptoms, its use increasing over time and with improving outcomes <span class="citation" data-cites="RN5">(<a href="#ref-RN5" role="doc-biblioref">5</a>)</span> (Figure 1). Patients referred for cardiac transplantation are required to undergo a significant amount of preprocedural testing <span class="citation" data-cites="RN4">(<a href="#ref-RN4" role="doc-biblioref">4</a>)</span> aimed at identifying potential contraindications. Patients deemed fit for transplantation typically undergo orthotopic heart transplantation, in which the native ventricles and all cardiac valves are excised, and anastomoses are created between the atria, aorta, and pulmonary valves of the donor and the recipient; in contrast, in patients undergoing heterotopic heart transplantation, the recipient heart is left in place and connected to the donor heart. As short-term survival improves (~85-90% at 1 year, and 75% at 5 years <span class="citation" data-cites="RN5">(<a href="#ref-RN5" role="doc-biblioref">5</a>)</span>), a growing number of patients are now followed up well beyond the 10th, 20th, or even 30th year since transplantation, which require extensive follow-up for the prevention of long-term complications.</p>
<div class="quarto-figure quarto-figure-center">
<figure class="figure">
<p><img src="images/phd/1.png" class="img-fluid figure-img"></p>
<figcaption>Figure 1 – Rate of heart transplants worldwide, 2011-2022 (Transplant Observatory, adapted).</figcaption>
</figure>
</div>
<section id="complications-following-cardiac-transplantation" class="level3">
<h3 class="anchored" data-anchor-id="complications-following-cardiac-transplantation">Complications following cardiac transplantation</h3>
<p>Notwithstanding the inherent risks of cardiac surgery, heart transplantation recipients are at risk of early- and late-onset complications, which will be briefly outlined (Figure 2). Cardiac allograft vasculopathy, a late-onset complication, will be discussed in detail in a separate section.</p>
<div class="quarto-figure quarto-figure-center">
<figure class="figure">
<p><img src="images/phd/2.png" class="img-fluid figure-img"></p>
<figcaption>Figure 2 – Main complications following cardiac transplantation.</figcaption>
</figure>
</div>
<p>In the early days up until the first years following cardiac transplantation, the graft recipient is at risk of developing heart failure and acute rejection, which is the leading cause of death in this period. Immunosuppressive therapy which is required for control of the immune response leads to opportunistic infections which typically occur between 30 days and the first year from the procedure. Cardiac allograft vasculopathy is commonly found in patients at &gt; 2 years from transplantation and is partially addressable with pharmacological treatment. Other late complications of cardiac transplantation include malignancies – mainly as a consequence of viral infections, chronic kidney disease (CKD), and the onset of diabetes, hypertension, dyslipidemia, depression and anxiety, gout, and osteoporosis <span class="citation" data-cites="RN6">(<a href="#ref-RN6" role="doc-biblioref">6</a>)</span>.</p>
<section id="primary-graft-dysfunction" class="level4">
<h4 class="anchored" data-anchor-id="primary-graft-dysfunction">Primary graft dysfunction</h4>
<p>This is defined as the failure of graft function in the first 24 hours after transplantation, which is not caused by concomitant rejection, pulmonary hypertension or procedural complications. Primary graft dysfunction has variable incidence (rates of 3-28% have been reported <span class="citation" data-cites="RN4">(<a href="#ref-RN4" role="doc-biblioref">4</a>)</span>) and is associated with poor short-term survival. It manifests itself with diastolic dysfunction and a restrictive pattern, associated with atrioventricular and aortic valve regurgitation which is typically asymptomatic.</p>
</section>
<section id="graft-rejection" class="level4">
<h4 class="anchored" data-anchor-id="graft-rejection">Graft rejection</h4>
<p>Rejection caused by activation of the recipient immune system, and categorised as antibody- or cell-mediated based on the predominant component in the immune response. While cell-mediated rejection occurs acutely in the first after transplantation, antibody-mediated rejection may be developed later on. Incidence of rejection is estimated at 13% in the first year since discharge, and it is recognized a major contributor to mortality <span class="citation" data-cites="RN7">(<a href="#ref-RN7" role="doc-biblioref">7</a>)</span> in the first three years from transplantation. Detection of rejection requires patients to regularly undergo endomyocardial biopsy, and histological grading is based on criteria proposed by the International Society for Heart and Lung Transplantation (ISHLT) <span class="citation" data-cites="RN8">(<a href="#ref-RN8" role="doc-biblioref">8</a>)</span>.</p>
</section>
<section id="infections" class="level4">
<h4 class="anchored" data-anchor-id="infections">Infections</h4>
<p>As a consequence of the use of immunosuppressive therapy, infections are the first cause of death between 30 days and 1 year since transplantation <span class="citation" data-cites="RN9">(<a href="#ref-RN9" role="doc-biblioref">9</a>)</span>. After the first year, immunosuppression is typically gradually decreased, but infections remain among the top three causes of death in the long term, with an attributable mortality of &gt; 10% <span class="citation" data-cites="RN7">(<a href="#ref-RN7" role="doc-biblioref">7</a>)</span>.</p>
</section>
<section id="other-late-complications" class="level4">
<h4 class="anchored" data-anchor-id="other-late-complications">Other late complications</h4>
<p>New onset of a malignancy following cardiac transplantation is estimated at 11% between 1 and 5 years from the procedure <span class="citation" data-cites="RN4">(<a href="#ref-RN4" role="doc-biblioref">4</a>)</span> and is mainly related to viral infections from agents such as the human papilloma virus, Epstein-Barr virus, and human herpes virus 8. Other common late-onset complications include diabetes, hypertension, dyslipidemia, and renal dysfunction, as well as psychological disorders, gout, and osteoporosis <span class="citation" data-cites="RN6">(<a href="#ref-RN6" role="doc-biblioref">6</a>)</span>.</p>
</section>
</section>
<section id="cardiac-allograft-vasculopathy" class="level3">
<h3 class="anchored" data-anchor-id="cardiac-allograft-vasculopathy">Cardiac allograft vasculopathy</h3>
<p>Cardiac allograft vasculopathy (CAV) has been labelled the «Achilles heel» of cardiac transplantation <span class="citation" data-cites="RN10">(<a href="#ref-RN10" role="doc-biblioref">10</a>)</span>. It consists in the diffuse intimal thickening and luminal narrowing in the coronary tree, possibly leading to focal occlusion and heart failure, with no or limited development of new collateral vessels11. Patients with CAV are often asymptomatic due to graft denervation <span class="citation" data-cites="RN2 RN11">(<a href="#ref-RN2" role="doc-biblioref">2</a>,<a href="#ref-RN11" role="doc-biblioref">11</a>)</span>, and both epicardial <span class="citation" data-cites="RN12">(<a href="#ref-RN12" role="doc-biblioref">12</a>)</span> and microvascular disease <span class="citation" data-cites="RN13">(<a href="#ref-RN13" role="doc-biblioref">13</a>)</span> were separately found to be prognostic. CAV is believed to be the result of an interplay of immunological and non-immunological factors which contribute to lipid deposition and proliferation of smooth muscle cells and macrophages in the intima2 of both epicardial vessels and the coronary microcirculation (Figure 3).</p>
<div class="quarto-figure quarto-figure-center">
<figure class="figure">
<p><img src="images/phd/3.png" class="img-fluid figure-img"></p>
<figcaption>Figure 3 – Typical atherosclerosis and allograft vasculopathy. (Adapted from Avery 2003)</figcaption>
</figure>
</div>
<p>Risk of CAV is associated with graft age, with incidence estimated at 8% at 1 year and 47% at 10 years <span class="citation" data-cites="RN4">(<a href="#ref-RN4" role="doc-biblioref">4</a>)</span>. The Stanford classification for CAV is descriptive of the morphological features at angiography. It distinguishes discrete lesions (type A) from distal diffuse concentric narrowing in main vessels (type B) or distal branches (type C) <span class="citation" data-cites="RN11">(<a href="#ref-RN11" role="doc-biblioref">11</a>)</span>. CAV grading is based on criteria proposed by the Cardiac Transplant Research Database, a multicenter registry that collected data from 4,637 invasive angiograms across 39 institutions in the 1990s <span class="citation" data-cites="RN14">(<a href="#ref-RN14" role="doc-biblioref">14</a>)</span>. This grading has been embraced by the ISHLT <span class="citation" data-cites="RN10">(<a href="#ref-RN10" role="doc-biblioref">10</a>)</span>, and defines CAV as pictured in Figure 4.</p>
<div class="quarto-figure quarto-figure-center">
<figure class="figure">
<p><img src="images/phd/4.png" class="img-fluid figure-img"></p>
<figcaption>Figure 4 – CAV grading according to the ISHLT.</figcaption>
</figure>
</div>
<p>Additionally, CAV should be managed in light of the clinical context. Rapidly progressing CAV in the first 2 years since transplantation is believed to be mainly driven by vasculitis and should be managed more aggressively due to its poor prognosis. Instead, a later (&gt; 2 years) presentation in the presence of preserved graft function is typical of an indolent course. Finally, rapidly progressive CAV is defined as new-onset CAV within 1 year of a previous normal angiogram; this is also associated with poor prognosis <span class="citation" data-cites="RN10">(<a href="#ref-RN10" role="doc-biblioref">10</a>)</span>.</p>
<p>Due to the diffuse involvement of the coronary tree, revascularization is rarely an option in patients with significant (i.e.&nbsp;moderate or severe) CAV <span class="citation" data-cites="RN15">(<a href="#ref-RN15" role="doc-biblioref">15</a>)</span> and is ultimately considered a palliative treatment with no survival benefit <span class="citation" data-cites="RN16">(<a href="#ref-RN16" role="doc-biblioref">16</a>)</span>. However, pharmacological treatment has been proven useful to hamper disease progression. Use of pravastatin reduced progression in intimal thickening in an open-label, randomized clinical trial <span class="citation" data-cites="RN17">(<a href="#ref-RN17" role="doc-biblioref">17</a>)</span>. Inhibitors of the mammalian target of rapamycin such as sirolimus have also shown to reduce CAV progression <span class="citation" data-cites="RN18">(<a href="#ref-RN18" role="doc-biblioref">18</a>)</span>.</p>
<section id="established-and-proposed-strategies-for-cav-surveillance" class="level4">
<h4 class="anchored" data-anchor-id="established-and-proposed-strategies-for-cav-surveillance">Established and proposed strategies for CAV surveillance</h4>
<p>Several single-modal or multimodal imaging strategies have been proposed for CAV detection and surveillance following cardiac transplantation. The benefits and drawbacks for each modality will be briefly outlined; a subsequent, specific section will discuss use of stress CMR imaging.</p>
<section id="invasive-coronary-angiography-ica" class="level5">
<h5 class="anchored" data-anchor-id="invasive-coronary-angiography-ica">Invasive coronary angiography (ICA)</h5>
<p>Due to the extensive evidence available for its use, ICA is considered the gold standard for CAV detection <span class="citation" data-cites="RN10">(<a href="#ref-RN10" role="doc-biblioref">10</a>)</span>. ICA is highly accessible to both pediatric and adult patients. However, routine, repeated use of invasive coronary angiography for CAV detection since the first years following cardiac transplantation has long been questioned<span class="citation" data-cites="RN15 RN19 RN20">(<a href="#ref-RN15" role="doc-biblioref">15</a>,<a href="#ref-RN19" role="doc-biblioref">19</a>,<a href="#ref-RN20" role="doc-biblioref">20</a>)</span>. Arguments against the use of invasive coronary angiography include the immediate risk of harm and radiation exposure, the palliative nature of revascularization – CAV being a diffuse, slowly progressing disease – along with the reported reduced sensitivity when compared with other techniques, notably intravascular ultrasound <span class="citation" data-cites="RN21">(<a href="#ref-RN21" role="doc-biblioref">21</a>)</span>. Despite these considerations, ICA remains the recommended procedure for CAV detection and surveillance.</p>
</section>
<section id="intravascular-ultrasound-ivus" class="level5">
<h5 class="anchored" data-anchor-id="intravascular-ultrasound-ivus">Intravascular ultrasound (IVUS)</h5>
<p>Use of IVUS has long been investigated in the transplant outpatient setting <span class="citation" data-cites="RN22">(<a href="#ref-RN22" role="doc-biblioref">22</a>)</span>, helping to shed light on CAV pathophysiology <span class="citation" data-cites="RN10">(<a href="#ref-RN10" role="doc-biblioref">10</a>)</span>. The 2010 ISHLT statement on CAV shared consensus that IVUS is most useful for its negative predictive value <span class="citation" data-cites="RN10">(<a href="#ref-RN10" role="doc-biblioref">10</a>)</span>. Additionally, despite recognizing its high sensitivity, the panel deemed use of IVUS as «investigational» and advocated that ICA should be instead used to guide patient management. However, IVUS has been showed to effectively select patients benefiting from subsequent routine invasive angiography <span class="citation" data-cites="RN23">(<a href="#ref-RN23" role="doc-biblioref">23</a>)</span>.</p>
</section>
<section id="dobutamine-stress-echocardiography" class="level5">
<h5 class="anchored" data-anchor-id="dobutamine-stress-echocardiography">Dobutamine stress echocardiography</h5>
<p>Echocardiography with dobutamine stress was found to be prognostic <span class="citation" data-cites="RN24">(<a href="#ref-RN24" role="doc-biblioref">24</a>)</span> and predictive of CAV <span class="citation" data-cites="RN25">(<a href="#ref-RN25" role="doc-biblioref">25</a>)</span> among heart transplant recipients, with impairment in strain parameters observed even in the presence of mild CAV <span class="citation" data-cites="RN26">(<a href="#ref-RN26" role="doc-biblioref">26</a>)</span>. However, when compared to CTCA against a reference of ICA, it was shown to be less sensitive <span class="citation" data-cites="RN27">(<a href="#ref-RN27" role="doc-biblioref">27</a>)</span>; later on, larger studies were conducted showing variable accuracy<span class="citation" data-cites="RN28 RN29 RN30">(<a href="#ref-RN28" role="doc-biblioref">28</a>–<a href="#ref-RN30" role="doc-biblioref">30</a>)</span> which culminated in a systematic review and meta-analysis finding highly variable sensitivity and variable specificity <span class="citation" data-cites="RN31">(<a href="#ref-RN31" role="doc-biblioref">31</a>)</span>. Authors concluded that the modality would be unlikely to yield enough positive and negative predictive value to effectively gatekeep patients to angiography.</p>
</section>
<section id="positron-emission-tomography-and-single-photon-emission-ct" class="level5">
<h5 class="anchored" data-anchor-id="positron-emission-tomography-and-single-photon-emission-ct">Positron emission tomography and single photon emission CT</h5>
<p>Positron emission tomography (PET) and single photon emission CT (SPECT) are perfusion imaging modalities variably implemented in the follow-up of cardiac transplantation. Quantification of MBF by PET was diagnostic for CAV <span class="citation" data-cites="RN32">(<a href="#ref-RN32" role="doc-biblioref">32</a>)</span> and prognostic at mid-term follow-up <span class="citation" data-cites="RN33">(<a href="#ref-RN33" role="doc-biblioref">33</a>)</span>. A later study showed superior discriminative ability of MPR over stress MBF <span class="citation" data-cites="RN34">(<a href="#ref-RN34" role="doc-biblioref">34</a>)</span>. Similarly, SPECT was found to be diagnostic against ICA <span class="citation" data-cites="RN35">(<a href="#ref-RN35" role="doc-biblioref">35</a>)</span>, but later reports found very low (&lt; 10%) sensitivity <span class="citation" data-cites="RN36">(<a href="#ref-RN36" role="doc-biblioref">36</a>)</span> and overall unacceptable accuracy <span class="citation" data-cites="RN37">(<a href="#ref-RN37" role="doc-biblioref">37</a>)</span>, warranting against use of SPECT to gatekeep angiography. Finally, a SPECT system utilizing cadmium-zinc-telluride crystals, allowing for direct measurement of MBF and MPR, was recently validated against PET in heart transplant recipients <span class="citation" data-cites="RN38">(<a href="#ref-RN38" role="doc-biblioref">38</a>)</span>, but the clinical utility of such technological advance remains unestablished <span class="citation" data-cites="RN39">(<a href="#ref-RN39" role="doc-biblioref">39</a>)</span>.</p>
</section>
<section id="ctca" class="level5">
<h5 class="anchored" data-anchor-id="ctca">CTCA</h5>
<p>To date, several studies have assessed the diagnostic value of CTCA for CAV detection. Upon comparison with coronary MR angiography, it showed superior performance <span class="citation" data-cites="RN40">(<a href="#ref-RN40" role="doc-biblioref">40</a>)</span>, and protocols with low radiation burden were validated in transplant recipients<span class="citation" data-cites="RN41 RN42 RN43">(<a href="#ref-RN41" role="doc-biblioref">41</a>–<a href="#ref-RN43" role="doc-biblioref">43</a>)</span>. In a longitudinal outcomes study, a strategy of CTCA appeared safe and feasible in retrospect <span class="citation" data-cites="RN44">(<a href="#ref-RN44" role="doc-biblioref">44</a>)</span> and use of the modality gained momentum <span class="citation" data-cites="RN45 RN46">(<a href="#ref-RN45" role="doc-biblioref">45</a>,<a href="#ref-RN46" role="doc-biblioref">46</a>)</span>, despite the lack of high-level evidence (e.g.&nbsp;randomized trials, prospective comparative trials). Upon diagnostic meta-analysis, CTCA yielded high accuracy, with sensitivity and specificity &gt; 90% for 64-slice CTCA <span class="citation" data-cites="RN47">(<a href="#ref-RN47" role="doc-biblioref">47</a>)</span>. In a study on real-world implementation, CTCA granted excellent image quality in heart transplant recipients, however, in 25% of patients the scan was not deemed safe due mainly to renal impairment <span class="citation" data-cites="RN48">(<a href="#ref-RN48" role="doc-biblioref">48</a>)</span>. Notably, the literature on accuracy of CTCA mainly focused on epicardial CAV with ICA as the reference test, and no comparative studies assessed the modality against IVUS. A recent study <span class="citation" data-cites="RN49">(<a href="#ref-RN49" role="doc-biblioref">49</a>)</span> evaluated the combination of anatomical assessment of CTCA with CT-based myocardial perfusion imaging, showing feasible microvascular evaluation with CT. Overall, the literature on CTCA for CAV showed safety and feasibility with some remaining concerns of real-world application. Additionally, use of CTCA for CAV surveillance would require a separate test for detecting allograft rejection.</p>
</section>
</section>
<section id="cmr-for-cav-surveillance" class="level4">
<h4 class="anchored" data-anchor-id="cmr-for-cav-surveillance">CMR for CAV surveillance</h4>
<p>We conducted a systematic literature review to appraise the investigation of CMR in the follow-up of heart transplant recipients (PROSPERO: CRD42023435640). Over the last two decades, several studies have evaluated CMR in the context of allograft rejection<span class="citation" data-cites="RN50 RN51 RN52 RN53 RN54 RN55 RN56 RN57 RN58 RN59 RN60 RN61 RN62">(<a href="#ref-RN50" role="doc-biblioref">50</a>–<a href="#ref-RN62" role="doc-biblioref">62</a>)</span> and CAV<span class="citation" data-cites="RN63 RN64 RN65 RN66 RN67 RN68 RN69 RN70 RN71 RN72 RN73 RN74">(<a href="#ref-RN63" role="doc-biblioref">63</a>–<a href="#ref-RN74" role="doc-biblioref">74</a>)</span>. In total, 15 studies were identified regarding use of CMR in CAV (Table 1).</p>
<div class="quarto-figure quarto-figure-center">
<figure class="figure">
<p><img src="images/phd/tbl1.png" class="img-fluid figure-img"></p>
<figcaption>Table 1 – Studies evaluating the use of CMR for CAV surveillance.</figcaption>
</figure>
</div>
<p>Over the course of 20 years, 15 studies evaluated the use of various CMR components to adjudicate presence or severity of CAV. Sample size refers to the number of heart transplant recipients enrolled to a study.</p>
</section>
</section>
</section>
<section id="methods" class="level2">
<h2 class="anchored" data-anchor-id="methods">Methods</h2>
<section id="design" class="level3">
<h3 class="anchored" data-anchor-id="design">Design</h3>
</section>
<section id="study-cases" class="level3">
<h3 class="anchored" data-anchor-id="study-cases">Study cases</h3>
</section>
<section id="procedures-and-tests" class="level3">
<h3 class="anchored" data-anchor-id="procedures-and-tests">Procedures and tests</h3>
<section id="cmr" class="level4">
<h4 class="anchored" data-anchor-id="cmr">CMR</h4>
</section>
<section id="angiography" class="level4">
<h4 class="anchored" data-anchor-id="angiography">Angiography</h4>
</section>
</section>
<section id="follow-up" class="level3">
<h3 class="anchored" data-anchor-id="follow-up">Follow-up</h3>
</section>
<section id="data-collection" class="level3">
<h3 class="anchored" data-anchor-id="data-collection">Data collection</h3>
</section>
<section id="statistics" class="level3">
<h3 class="anchored" data-anchor-id="statistics">Statistics</h3>
<section id="diagnostic-accuracy" class="level4">
<h4 class="anchored" data-anchor-id="diagnostic-accuracy">Diagnostic accuracy</h4>
</section>
<section id="clinical-utility" class="level4">
<h4 class="anchored" data-anchor-id="clinical-utility">Clinical utility</h4>
</section>
<section id="prognostic-yield" class="level4">
<h4 class="anchored" data-anchor-id="prognostic-yield">Prognostic yield</h4>
</section>
</section>
</section>
<section id="results" class="level2">
<h2 class="anchored" data-anchor-id="results">Results</h2>
<section id="baseline-characteristics" class="level3">
<h3 class="anchored" data-anchor-id="baseline-characteristics">Baseline characteristics</h3>
</section>
<section id="angiographic-findings" class="level3">
<h3 class="anchored" data-anchor-id="angiographic-findings">Angiographic findings</h3>
</section>
<section id="cmr-findings" class="level3">
<h3 class="anchored" data-anchor-id="cmr-findings">CMR findings</h3>
</section>
<section id="stress-cmr-findings" class="level3">
<h3 class="anchored" data-anchor-id="stress-cmr-findings">Stress CMR findings</h3>
<section id="feasibility" class="level4">
<h4 class="anchored" data-anchor-id="feasibility">Feasibility</h4>
</section>
<section id="safety" class="level4">
<h4 class="anchored" data-anchor-id="safety">Safety</h4>
</section>
<section id="quantitative-perfusion-cmr" class="level4">
<h4 class="anchored" data-anchor-id="quantitative-perfusion-cmr">Quantitative perfusion CMR</h4>
</section>
</section>
<section id="diagnostic-accuracy-1" class="level3">
<h3 class="anchored" data-anchor-id="diagnostic-accuracy-1">Diagnostic accuracy</h3>
<section id="inducible-ischemia-on-visual-inspection" class="level4">
<h4 class="anchored" data-anchor-id="inducible-ischemia-on-visual-inspection">Inducible ischemia on visual inspection</h4>
</section>
<section id="mpr-index" class="level4">
<h4 class="anchored" data-anchor-id="mpr-index">MPR index</h4>
</section>
<section id="stress-mbf" class="level4">
<h4 class="anchored" data-anchor-id="stress-mbf">Stress MBF</h4>
</section>
<section id="rest-mbf-index" class="level4">
<h4 class="anchored" data-anchor-id="rest-mbf-index">Rest MBF index</h4>
</section>
<section id="quantitative-stress-perfusion-cmr-and-donor-specific-antibodies" class="level4">
<h4 class="anchored" data-anchor-id="quantitative-stress-perfusion-cmr-and-donor-specific-antibodies">Quantitative stress perfusion CMR and donor-specific antibodies</h4>
</section>
</section>
<section id="clinical-utility-1" class="level3">
<h3 class="anchored" data-anchor-id="clinical-utility-1">Clinical utility</h3>
<section id="correction-for-overfit" class="level4">
<h4 class="anchored" data-anchor-id="correction-for-overfit">Correction for overfit</h4>
</section>
</section>
<section id="prognostic-yield-1" class="level3">
<h3 class="anchored" data-anchor-id="prognostic-yield-1">Prognostic yield</h3>
<section id="baseline-characteristics-1" class="level4">
<h4 class="anchored" data-anchor-id="baseline-characteristics-1">Baseline characteristics</h4>
</section>
<section id="stress-cmr-parameters" class="level4">
<h4 class="anchored" data-anchor-id="stress-cmr-parameters">Stress CMR parameters</h4>
</section>
<section id="other-cmr-parameters" class="level4">
<h4 class="anchored" data-anchor-id="other-cmr-parameters">Other CMR parameters</h4>
</section>
</section>
</section>
<section id="discussion" class="level2">
<h2 class="anchored" data-anchor-id="discussion">Discussion</h2>
<p>A 2010 consensus statement issued by the ISHLT defined ICA as a «screening tool to grossly detect the presence of CAV» <span class="citation" data-cites="RN10">(<a href="#ref-RN10" role="doc-biblioref">10</a>)</span>. This statement may be seen as controversial given earlier reports of limited utility of ICA in the setting of cardiac transplantation <span class="citation" data-cites="RN15">(<a href="#ref-RN15" role="doc-biblioref">15</a>)</span>, the radiological risk associated with repeated, typically yearly, testing, and the significant periprocedural complication rate, which is to be balanced against limited, where not not null, interventional benefit <span class="citation" data-cites="RN16">(<a href="#ref-RN16" role="doc-biblioref">16</a>)</span>. IVUS has been shown to yield increased sensitivity and might be used to select patients in need of closer mid-term surveillance <span class="citation" data-cites="RN23">(<a href="#ref-RN23" role="doc-biblioref">23</a>)</span>, but it does not address the issue of risk and requires additional expertise. It is also subject to variable local availability.</p>
<p>To date, dobutamine stress echocardiography had low diagnostic yield for CAV <span class="citation" data-cites="RN31">(<a href="#ref-RN31" role="doc-biblioref">31</a>)</span>. SPECT may not be considered as a diagnostic gatekeeper to ICA due to its unacceptable accuracy <span class="citation" data-cites="RN36">(<a href="#ref-RN36" role="doc-biblioref">36</a>)</span>, and while novel advances in MBF and MPR quantification were recently validated <span class="citation" data-cites="RN38">(<a href="#ref-RN38" role="doc-biblioref">38</a>)</span>, these are far from widespread clinical implementation. Potential noninvasive gatekeeper tests include CTCA, PET and stress CMR <span class="citation" data-cites="RN39">(<a href="#ref-RN39" role="doc-biblioref">39</a>)</span>. CTCA currently holds a central role in CAV as it allows to image the coronary arteries with great detail <span class="citation" data-cites="RN84">(<a href="#ref-RN84" role="doc-biblioref">75</a>)</span>. However, radiological risk is nonnegligible with CTCA as with ICA <span class="citation" data-cites="RN85">(<a href="#ref-RN85" role="doc-biblioref">76</a>)</span>, being especially high in young patients <span class="citation" data-cites="RN86">(<a href="#ref-RN86" role="doc-biblioref">77</a>)</span> and cumulated with repeated scans, which would be recommended at a frequency of every two years in heart transplant recipients <span class="citation" data-cites="RN44">(<a href="#ref-RN44" role="doc-biblioref">44</a>)</span>. Despite the growing interest in tissue characterisation and CT perfusion, these remain purely investigational and evidence is lacking that CTCA might offer a “one-stop shop” for CAV surveillance and rejection. Bearing in mind that patients with a previous cardiac transplantation face significant risks for different complications, including graft rejection and CAV, it seems highly unlikely that CTCA might allow to reduce rates of utilization of endomyocardial biopsy and invasive coronary angiography; the same goes for PET, which might have high yield in CAV, but has no established value in the context of graft rejection, confers radiation exposure, and has limited worldwide availability and expertise <span class="citation" data-cites="RN87">(<a href="#ref-RN87" role="doc-biblioref">78</a>)</span>.</p>
<p>We now have high-level evidence from a randomized controlled trial that a CMR strategy is non-inferior to an invasive strategy of endomyocardial biopsy in the setting of graft rejection surveillance <span class="citation" data-cites="RN62">(<a href="#ref-RN62" role="doc-biblioref">62</a>)</span>. This raises the bar in terms of patient needs following cardiac transplantation; as we are able to prevent more and more patients from undergoing unnecessary biopsies, it appears just as reasonable to pursue diagnostic strategies that reduce unnecessary angiographies for CAV detection and surveillance. Noninvasive strategies allowing for quantification of myocardial blood flow for CAV assessment include PET <span class="citation" data-cites="RN32 RN33">(<a href="#ref-RN32" role="doc-biblioref">32</a>,<a href="#ref-RN33" role="doc-biblioref">33</a>)</span> and CMR<span class="citation" data-cites="RN69 RN73 RN88 RN89">(<a href="#ref-RN69" role="doc-biblioref">69</a>,<a href="#ref-RN73" role="doc-biblioref">73</a>,<a href="#ref-RN88" role="doc-biblioref">79</a>,<a href="#ref-RN89" role="doc-biblioref">80</a>)</span>, with preliminary findings for SPECT <span class="citation" data-cites="RN90">(<a href="#ref-RN90" role="doc-biblioref">81</a>)</span> and CT <span class="citation" data-cites="RN49">(<a href="#ref-RN49" role="doc-biblioref">49</a>)</span>.</p>
<p>In our study, we observed adenosine stress perfusion CMR to be safe and feasible in a substantial cohort of heart transplant recipients, with 25% stressed at &lt; 3 years from transplantation, and able to elicit adequate cardiovascular and symptomatic responses.</p>
<p>We find assessment of quantitative stress perfusion cardiac MRI as a viable, noninvasive, radiation-free alternative to angiography, which provides acceptable rule-in and excellent rule-out ability, has incremental prognostic value, and high decisional performance in a real-world outpatient population of heart transplant recipients. In particular, we found in the MPR index, as measured in-line during the scan, a single parameter which would confer operational accuracy in CAV detection, with limited added value from other parameters such as stress MBF and rest MBF index. Importantly, we confirm results from a previous, non-comparative study in which qualitative assessment of inducible myocardial ischemia had poor diagnostic value in CAV <span class="citation" data-cites="RN64">(<a href="#ref-RN64" role="doc-biblioref">64</a>)</span>. We build on that finding by showing not only that quantitative stress perfusion CMR has incremental value over qualitative assessment of ischemia, but also that it might lead to a major reduction in the use of ICA and CTCA, with a net benefit in terms of newly-diagnosed patients which largely outweighs any missed diagnoses and fits well within diverse decision-making frameworks. These results on the clinical utility of quantitative stress perfusion CMR do not consider the additional benefit conferred by reduction in radiation exposure, for both CTCA and ICA, and relative harm and costs of ICA. The single parameter with the greatest accuracy (~79%) was MPR index, while all other parameters at rest and stress had smaller AUCs at ~60-70%.</p>
<p>We also evaluated the prognostic value of stress CMR long-term after heart transplantation. Our results on adenosine stress perfusion CMR expand on previous work on risk prediction by qualitative regadenoson stress CMR <span class="citation" data-cites="RN88 RN91">(<a href="#ref-RN88" role="doc-biblioref">79</a>,<a href="#ref-RN91" role="doc-biblioref">82</a>)</span> and semi-quantitative MPR index measurement with adenosine <span class="citation" data-cites="RN92">(<a href="#ref-RN92" role="doc-biblioref">83</a>)</span>. In their study, Kazmirczak, Shenoy and colleagues88 showed that an abnormal stress CMR was prognostic for a composite endpoint of composite endpoint of myocardial infarction, percutaneous revascularization, cardiac hospitalization, retransplantation or death. However, they reported on prognostic yield of broad CMR assessment, comprehensive of LV function, scarring and inducible myocardial ischemia upon visual inspection. We instead report, for the first time, on the specific prognostic value of fully quantitative perfusion parameters in patients with suspected CAV. These results can be weighed against the corresponding PET literature <span class="citation" data-cites="RN33 RN34">(<a href="#ref-RN33" role="doc-biblioref">33</a>,<a href="#ref-RN34" role="doc-biblioref">34</a>)</span>. With the present work, CMR and PET may be nominally equiparable in terms of their diagnostic and prognostic yield, but the current lack of comparative studies justifies the need for future prospective head-to-head evaluation.</p>
<p>We additionally report, for the first time to our knowledge, on a correlation between the rate-pressure product and MBF during stress, which is not observed in the general population or in the first years after cardiac transplantation76 (see <a href="#appendix">Appendix</a>). In this context, we demonstrate that such relationship is independent of the presence of CAV and might indicate the need for adjustment of the stress MBF for the stress RPP for this parameter to achieve greater diagnostic and prognostic yield. We further evaluated the influence of positivity to donor-specific antibodies on diagnostic accuracy metrics, specifically for stress rate-pressure product-adjusted stress MBF, which is found to be significantly reduced among patients with no significant CAV who are DSA-positive, hinting at possible microvascular dysfunction in relation with subclinical rejection (see <a href="#appendix">Appendix</a>).</p>
<p>In this study, quantitative perfusion was superior to qualitative stress perfusion CMR for CAV detection and patient prognostication. At present, stress CMR is infrequently utilized for CAV assessment <span class="citation" data-cites="RN87">(<a href="#ref-RN87" role="doc-biblioref">78</a>)</span>. Results of this study demonstrate the value of quantitative stress perfusion CMR for CAV surveillance in heart transplant recipients and warrant future validation in a prospective trial.</p>
</section>
<section id="limitations" class="level2">
<h2 class="anchored" data-anchor-id="limitations">Limitations</h2>
<p>This study has the following limitations. The observational, single-centre, retrospective study design allowed to demonstrate the safety, feasibility and clinical potential, but not the real-world effectiveness of a strategy of stress CMR as gatekeeper to angiography, which should be the objective of future research effort; time between CMR and angiography varied significantly among patients, possibly leading to imperfect comparison between the respective findings; in this study, both ICA and CTCA findings were utilized in a composite angiographic endpoint (and accepted as reported), whereas the latest ISHLT recommendations, despite being more than 12 years old, state that CTCA cannot be seen as an alternative to ICA for its lack of accuracy in assessing branch vessels; additionally, we found evidence of selection bias in referral to ICA versus CTCA, presumably owing to the real-world physician preference of CTCA in low-risk patients; we cannot exclude a biased representation of cardiac transplantation outpatients in this cohort, as patients not undergoing CMR, the stress component of CMR, or angiography for any reason were systematically excluded; additionally, we have not addressed the issue of donor-transmitted coronary artery disease versus new-onset CAV of the graft heart; we have not fully evaluated the additional value of quantitative stress perfusion CMR parameters compared with non-stress CMR parameters; we did not assess the applicability of parametric mapping to CAV assessment, for which there is some initial evidence74; although we confirmed the prognostic value of global longitudinal strain in this cohort as previously demonstrated93, we did not formally compare the diagnostic and prognostic yield of strain and perfusion modules, specifically because this was a study of patients undergoing stress CMR with a limited number of events. The study sample was adequate for detection of differences in quantitative perfusion parameters between patients with and without significant CAV, but may be considered modest for the prognostic analysis. This is reflective of practice of the outpatient surveillance service for cardiac transplantation recipients which does not routinely or exclusively refer patients to CMR.</p>
</section>
<section id="future-perspectives" class="level2">
<h2 class="anchored" data-anchor-id="future-perspectives">Future perspectives</h2>
<p>Our study results pave the way for a future prospective, multi-centre, randomized controlled trial to test the hypothesis that CMR-guided catheterisation is non-inferior to current angiography referral practice in terms of safety and efficacy, and leads to reduced downstream costs owing to a reduction in use of unnecessary ICA, in long-term heart transplant recipients. As different competing tests have been proposed as credible, non-invasive gatekeepers to angiography (mainly CTCA, PET, and CMR), prospective comparisons of these tests has been recommended against a diagnostic and prognostic endpoint <span class="citation" data-cites="RN39">(<a href="#ref-RN39" role="doc-biblioref">39</a>)</span>. Such a study design may be challenged by the slowly-progressing nature of CAV, and it is outside of the scope of the present work to indulge in power calculations or endpoint definitions. However, where a randomized controlled trial would be deemed unfeasible, quasi-randomized designs of interrupted time-series analysis and difference-in-difference studies might instead prove feasible, less costly, and possibly as informative <span class="citation" data-cites="RN94">(<a href="#ref-RN94" role="doc-biblioref">84</a>)</span>. Finally, methodological and implementational aspects of this proof-of-concept study will need future investigation. There is growing awareness of the need to make cardiovascular imaging increasingly sustainable from ethical, economic and environmental standpoints <span class="citation" data-cites="RN95">(<a href="#ref-RN95" role="doc-biblioref">85</a>)</span>. In this light, our study findings appear incomplete and should be weighed against the comparative yield and cost-effectiveness of stress CMR and other non-invasive imaging modalities in the cardiac transplant outpatient setting, which should be the object of future investigation.</p>
</section>
<section id="conclusion" class="level2">
<h2 class="anchored" data-anchor-id="conclusion">Conclusion</h2>
<p>In this retrospective observational study, stress CMR with quantitative perfusion showed excellent safety profile and feasibility in HT recipients. Quantitative stress perfusion CMR, but not qualitative stress CMR, was diagnostic for cardiac allograft vasculopathy and yielded superior decisional and prognostic performance, findings which substantiate its utility as a gatekeeper to invasive testing. These findings warrant prospective and comparative validation.</p>
</section>
<section id="references" class="level2">
<h2 class="anchored" data-anchor-id="references">References</h2>
<div id="refs" class="references csl-bib-body" data-entry-spacing="0" role="list">
<div id="ref-RN1" class="csl-entry" role="listitem">
<div class="csl-left-margin">1. </div><div class="csl-right-inline">Gulati M., Levy PD., Mukherjee D., et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: A report of the american college of cardiology/american heart association joint committee on clinical practice guidelines. Circulation 2021;144(22):e368–454. Doi: <a href="https://doi.org/10.1161/cir.0000000000001029">10.1161/cir.0000000000001029</a>.</div>
</div>
<div id="ref-RN2" class="csl-entry" role="listitem">
<div class="csl-left-margin">2. </div><div class="csl-right-inline">Avery RK. Cardiac-allograft vasculopathy. New England Journal of Medicine 2003;349(9):829–30. Doi: <a href="https://doi.org/10.1056/NEJMp038124">10.1056/NEJMp038124</a>.</div>
</div>
<div id="ref-RN3" class="csl-entry" role="listitem">
<div class="csl-left-margin">3. </div><div class="csl-right-inline">Ellenbogen KA., Thames MD., DiMarco JP., Sheehan H., Lerman BB. Electrophysiological effects of adenosine in the transplanted human heart. Evidence of supersensitivity. Circulation 1990;81(3):821–8. Doi: <a href="https://doi.org/10.1161/01.cir.81.3.821">10.1161/01.cir.81.3.821</a>.</div>
</div>
<div id="ref-RN4" class="csl-entry" role="listitem">
<div class="csl-left-margin">4. </div><div class="csl-right-inline">Sai Kiran B., Stephen P., Jayan P. Cardiac transplantation: Indications, eligibility and current outcomes. Heart 2019;105(3):252. Doi: <a href="https://doi.org/10.1136/heartjnl-2018-313103">10.1136/heartjnl-2018-313103</a>.</div>
</div>
<div id="ref-RN5" class="csl-entry" role="listitem">
<div class="csl-left-margin">5. </div><div class="csl-right-inline">Giblin G., Murphy L., Mahon N., et al. Survival trends post cardiac transplantation: A comparative analysis of irish and international data (1985-2019). The Journal of Heart and Lung Transplantation 2020;39(4, Supplement):S290. Doi: <a href="https://doi.org/10.1016/j.healun.2020.01.642">https://doi.org/10.1016/j.healun.2020.01.642</a>.</div>
</div>
<div id="ref-RN6" class="csl-entry" role="listitem">
<div class="csl-left-margin">6. </div><div class="csl-right-inline">Yamani MH., Starling RC. Long-term medical complications of heart transplantation: Information for the primary care physician. Cleve Clin J Med 2000;67(9):673–80. Doi: <a href="https://doi.org/10.3949/ccjm.67.9.673">10.3949/ccjm.67.9.673</a>.</div>
</div>
<div id="ref-RN7" class="csl-entry" role="listitem">
<div class="csl-left-margin">7. </div><div class="csl-right-inline">Lund LH., Khush KK., Cherikh WS., et al. The registry of the international society for heart and lung transplantation: Thirty-fourth adult heart transplantation report&amp;#x2014;2017; focus theme: Allograft ischemic time. The Journal of Heart and Lung Transplantation 2017;36(10):1037–46. Doi: <a href="https://doi.org/10.1016/j.healun.2017.07.019">10.1016/j.healun.2017.07.019</a>.</div>
</div>
<div id="ref-RN8" class="csl-entry" role="listitem">
<div class="csl-left-margin">8. </div><div class="csl-right-inline">Stewart S., Winters GL., Fishbein MC., et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. The Journal of Heart and Lung Transplantation 2005;24(11):1710–20. Doi: <a href="https://doi.org/10.1016/j.healun.2005.03.019">10.1016/j.healun.2005.03.019</a>.</div>
</div>
<div id="ref-RN9" class="csl-entry" role="listitem">
<div class="csl-left-margin">9. </div><div class="csl-right-inline">Avery RK. Infectious disease and transplantation: Messages for the generalist. Cleve Clin J Med 1998;65(6):305–14. Doi: <a href="https://doi.org/10.3949/ccjm.65.6.305">10.3949/ccjm.65.6.305</a>.</div>
</div>
<div id="ref-RN10" class="csl-entry" role="listitem">
<div class="csl-left-margin">10. </div><div class="csl-right-inline">Mehra MR., Crespo-Leiro MG., Dipchand A., et al. International society for heart and lung transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant 2010;29(7):717–27. Doi: <a href="https://doi.org/10.1016/j.healun.2010.05.017">10.1016/j.healun.2010.05.017</a>.</div>
</div>
<div id="ref-RN11" class="csl-entry" role="listitem">
<div class="csl-left-margin">11. </div><div class="csl-right-inline">Gao S-Z., Alderman EL., Schroeder JS., Silverman JF., Hunt SA. Accelerated coronary vascular disease in the heart transplant patient: Coronary arteriographic findings. Journal of the American College of Cardiology 1988;12(2):334–40. Doi: <a href="https://doi.org/10.1016/0735-1097(88)90402-0">https://doi.org/10.1016/0735-1097(88)90402-0</a>.</div>
</div>
<div id="ref-RN12" class="csl-entry" role="listitem">
<div class="csl-left-margin">12. </div><div class="csl-right-inline">Taylor DO., Edwards LB., Boucek MM., et al. Registry of the international society for heart and lung transplantation: Twenty-second official adult heart transplant report–2005. J Heart Lung Transplant 2005;24(8):945–55. Doi: <a href="https://doi.org/10.1016/j.healun.2005.05.018">10.1016/j.healun.2005.05.018</a>.</div>
</div>
<div id="ref-RN13" class="csl-entry" role="listitem">
<div class="csl-left-margin">13. </div><div class="csl-right-inline">Hiemann NE., Wellnhofer E., Knosalla C., et al. Prognostic impact of microvasculopathy on survival after heart transplantation: Evidence from 9713 endomyocardial biopsies. Circulation 2007;116(11):1274–82. Doi: <a href="https://doi.org/10.1161/circulationaha.106.647149">10.1161/circulationaha.106.647149</a>.</div>
</div>
<div id="ref-RN14" class="csl-entry" role="listitem">
<div class="csl-left-margin">14. </div><div class="csl-right-inline">Costanzo MR., Naftel DC., Pritzker MR., et al. Heart transplant coronary artery disease detected by coronary angiography: A multiinstitutional study of preoperative donor and recipient risk factors. Cardiac transplant research database. J Heart Lung Transplant 1998;17(8):744–53.</div>
</div>
<div id="ref-RN15" class="csl-entry" role="listitem">
<div class="csl-left-margin">15. </div><div class="csl-right-inline">Clague JR., Cox ID., Murday AJ., Charokopos N., Madden BP. Low clinical utility of routine angiographic surveillance in the detection and management of cardiac allograft vasculopathy in transplant recipients. Clin Cardiol 2001;24(6):459–62. Doi: <a href="https://doi.org/10.1002/clc.4960240608">10.1002/clc.4960240608</a>.</div>
</div>
<div id="ref-RN16" class="csl-entry" role="listitem">
<div class="csl-left-margin">16. </div><div class="csl-right-inline">Schmauss D., Weis M. Cardiac allograft vasculopathy. Circulation 2008;117(16):2131–41. Doi: <a href="https://doi.org/10.1161/CIRCULATIONAHA.107.711911">10.1161/CIRCULATIONAHA.107.711911</a>.</div>
</div>
<div id="ref-RN17" class="csl-entry" role="listitem">
<div class="csl-left-margin">17. </div><div class="csl-right-inline">Kobashigawa JA., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. New England Journal of Medicine 1995;333(10):621–7. Doi: <a href="https://doi.org/10.1056/nejm199509073331003">10.1056/nejm199509073331003</a>.</div>
</div>
<div id="ref-RN18" class="csl-entry" role="listitem">
<div class="csl-left-margin">18. </div><div class="csl-right-inline">Keogh A., Richardson M., Ruygrok P., et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years. Circulation 2004;110(17):2694–700. Doi: <a href="https://doi.org/10.1161/01.CIR.0000136812.90177.94">10.1161/01.CIR.0000136812.90177.94</a>.</div>
</div>
<div id="ref-RN19" class="csl-entry" role="listitem">
<div class="csl-left-margin">19. </div><div class="csl-right-inline">Grant SC., Brooks NH., Levy RD. Routine coronary angiography after heart transplantation. Heart 1997;78(2):101. Doi: <a href="https://doi.org/10.1136/hrt.78.2.101">10.1136/hrt.78.2.101</a>.</div>
</div>
<div id="ref-RN20" class="csl-entry" role="listitem">
<div class="csl-left-margin">20. </div><div class="csl-right-inline">Störk S., Behr TM., Birk M., et al. Assessment of cardiac allograft vasculopathy late after heart transplantation: When is coronary angiography necessary? J Heart Lung Transplant 2006;25(9):1103–8. Doi: <a href="https://doi.org/10.1016/j.healun.2006.05.009">10.1016/j.healun.2006.05.009</a>.</div>
</div>
<div id="ref-RN21" class="csl-entry" role="listitem">
<div class="csl-left-margin">21. </div><div class="csl-right-inline">Torres HJ., Merello L., Ramos SA., et al. Prevalence of cardiac allograft vasculopathy assessed with coronary angiography versus coronary vascular ultrasound and virtual histology. Transplant Proc 2011;43(6):2318–21. Doi: <a href="https://doi.org/10.1016/j.transproceed.2011.06.002">10.1016/j.transproceed.2011.06.002</a>.</div>
</div>
<div id="ref-RN22" class="csl-entry" role="listitem">
<div class="csl-left-margin">22. </div><div class="csl-right-inline">Kobashigawa JA., Tobis JM., Starling RC., et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: Outcomes after five years. Journal of the American College of Cardiology 2005;45(9):1532–7. Doi: <a href="https://doi.org/10.1016/j.jacc.2005.02.035">https://doi.org/10.1016/j.jacc.2005.02.035</a>.</div>
</div>
<div id="ref-RN23" class="csl-entry" role="listitem">
<div class="csl-left-margin">23. </div><div class="csl-right-inline">Nelson LM., Rossing K., Ihlemann N., Boesgaard S., Engstrøm T., Gustafsson F. Intravascular ultrasound-guided selection for early noninvasive cardiac allograft vasculopathy screening in heart transplant recipients. Clin Transplant 2020;34(12):e14124. Doi: <a href="https://doi.org/10.1111/ctr.14124">10.1111/ctr.14124</a>.</div>
</div>
<div id="ref-RN24" class="csl-entry" role="listitem">
<div class="csl-left-margin">24. </div><div class="csl-right-inline">Bacal F., Moreira L., Souza G., et al. Dobutamine stress echocardiography predicts cardiac events or death in asymptomatic patients long-term after heart transplantation: 4-year prospective evaluation. J Heart Lung Transplant 2004;23(11):1238–44. Doi: <a href="https://doi.org/10.1016/j.healun.2003.09.007">10.1016/j.healun.2003.09.007</a>.</div>
</div>
<div id="ref-RN25" class="csl-entry" role="listitem">
<div class="csl-left-margin">25. </div><div class="csl-right-inline">Dipchand AI., Bharat W., Manlhiot C., Safi M., Lobach NE., McCrindle BW. A prospective study of dobutamine stress echocardiography for the assessment of cardiac allograft vasculopathy in pediatric heart transplant recipients. Pediatr Transplant 2008;12(5):570–6. Doi: <a href="https://doi.org/10.1111/j.1399-3046.2007.00861.x">10.1111/j.1399-3046.2007.00861.x</a>.</div>
</div>
<div id="ref-RN26" class="csl-entry" role="listitem">
<div class="csl-left-margin">26. </div><div class="csl-right-inline">Eroglu E., D’Hooge J., Sutherland GR., et al. Quantitative dobutamine stress echocardiography for the early detection of cardiac allograft vasculopathy in heart transplant recipients. Heart 2008;94(2):e3. Doi: <a href="https://doi.org/10.1136/hrt.2007.119693">10.1136/hrt.2007.119693</a>.</div>
</div>
<div id="ref-RN27" class="csl-entry" role="listitem">
<div class="csl-left-margin">27. </div><div class="csl-right-inline">Mastrobuoni S., Bastarrika G., Ubilla M., et al. Dual-source CT coronary angiogram in heart transplant recipients in comparison with dobutamine stress echocardiography for detection of cardiac allograft vasculopathy. Transplantation 2009;87(4):587–90. Doi: <a href="https://doi.org/10.1097/TP.0b013e318195a5a7">10.1097/TP.0b013e318195a5a7</a>.</div>
</div>
<div id="ref-RN28" class="csl-entry" role="listitem">
<div class="csl-left-margin">28. </div><div class="csl-right-inline">Minardi G., Zampi G., Pergolini A., et al. The pressure/volume relationship during dobutamine stress echocardiography in transplanted heart: Comparison with quality of life and coronary anatomy. Cardiovasc Ultrasound 2012;10:44. Doi: <a href="https://doi.org/10.1186/1476-7120-10-44">10.1186/1476-7120-10-44</a>.</div>
</div>
<div id="ref-RN29" class="csl-entry" role="listitem">
<div class="csl-left-margin">29. </div><div class="csl-right-inline">Sade LE., Eroğlu S., Yüce D., et al. Follow-up of heart transplant recipients with serial echocardiographic coronary flow reserve and dobutamine stress echocardiography to detect cardiac allograft vasculopathy. J Am Soc Echocardiogr 2014;27(5):531–9. Doi: <a href="https://doi.org/10.1016/j.echo.2014.01.020">10.1016/j.echo.2014.01.020</a>.</div>
</div>
<div id="ref-RN30" class="csl-entry" role="listitem">
<div class="csl-left-margin">30. </div><div class="csl-right-inline">Chirakarnjanakorn S., Starling RC., Popović ZB., Griffin BP., Desai MY. Dobutamine stress echocardiography during follow-up surveillance in heart transplant patients: Diagnostic accuracy and predictors of outcomes. J Heart Lung Transplant 2015;34(5):710–7. Doi: <a href="https://doi.org/10.1016/j.healun.2014.11.019">10.1016/j.healun.2014.11.019</a>.</div>
</div>
<div id="ref-RN31" class="csl-entry" role="listitem">
<div class="csl-left-margin">31. </div><div class="csl-right-inline">Elkaryoni A., Abu-Sheasha G., Altibi AM., Hassan A., Ellakany K., Nanda NC. Diagnostic accuracy of dobutamine stress echocardiography in the detection of cardiac allograft vasculopathy in heart transplant recipients: A systematic review and meta-analysis study. Echocardiography 2019;36(3):528–36. Doi: <a href="https://doi.org/10.1111/echo.14268">10.1111/echo.14268</a>.</div>
</div>
<div id="ref-RN32" class="csl-entry" role="listitem">
<div class="csl-left-margin">32. </div><div class="csl-right-inline">Chih S., Chong AY., Erthal F., et al. PET assessment of epicardial intimal disease and microvascular dysfunction in cardiac allograft vasculopathy. J Am Coll Cardiol 2018;71(13):1444–56. Doi: <a href="https://doi.org/10.1016/j.jacc.2018.01.062">10.1016/j.jacc.2018.01.062</a>.</div>
</div>
<div id="ref-RN33" class="csl-entry" role="listitem">
<div class="csl-left-margin">33. </div><div class="csl-right-inline">Bravo PE., Bergmark BA., Vita T., et al. Diagnostic and prognostic value of myocardial blood flow quantification as non-invasive indicator of cardiac allograft vasculopathy. Eur Heart J 2018;39(4):316–23. Doi: <a href="https://doi.org/10.1093/eurheartj/ehx683">10.1093/eurheartj/ehx683</a>.</div>
</div>
<div id="ref-RN34" class="csl-entry" role="listitem">
<div class="csl-left-margin">34. </div><div class="csl-right-inline">Robert JHM., Osamu M., Balaji T., et al. Comparative prognostic and diagnostic value of myocardial blood flow and myocardial flow reserve after cardiac transplantation. Journal of Nuclear Medicine 2020;61(2):249. Doi: <a href="https://doi.org/10.2967/jnumed.119.229625">10.2967/jnumed.119.229625</a>.</div>
</div>
<div id="ref-RN35" class="csl-entry" role="listitem">
<div class="csl-left-margin">35. </div><div class="csl-right-inline">Wu YW., Yen RF., Lee CM., et al. Diagnostic and prognostic value of dobutamine thallium-201 single-photon emission computed tomography after heart transplantation. J Heart Lung Transplant 2005;24(5):544–50. Doi: <a href="https://doi.org/10.1016/j.healun.2003.12.004">10.1016/j.healun.2003.12.004</a>.</div>
</div>
<div id="ref-RN36" class="csl-entry" role="listitem">
<div class="csl-left-margin">36. </div><div class="csl-right-inline">Thompson D., Koster MJ., Wagner RH., Heroux A., Barron JT. Single photon emission computed tomography myocardial perfusion imaging to detect cardiac allograft vasculopathy. Eur Heart J Cardiovasc Imaging 2012;13(3):271–5. Doi: <a href="https://doi.org/10.1093/ejechocard/jer270">10.1093/ejechocard/jer270</a>.</div>
</div>
<div id="ref-RN37" class="csl-entry" role="listitem">
<div class="csl-left-margin">37. </div><div class="csl-right-inline">Aguilar J., Miller RJH., Otaki Y., et al. Clinical utility of SPECT in the heart transplant population: Analysis from a single large-volume center. Transplantation 2022;106(3):623–32. Doi: <a href="https://doi.org/10.1097/tp.0000000000003791">10.1097/tp.0000000000003791</a>.</div>
</div>
<div id="ref-RN38" class="csl-entry" role="listitem">
<div class="csl-left-margin">38. </div><div class="csl-right-inline">Ko KY., Ko CL., Lee CM., et al. Myocardial flow assessment after heart transplantation using dynamic cadmium-zinc-telluride single-photon emission computed tomography with (201)tl and (99m)tc tracers and validated by (13)n-NH(3) positron emission tomography. Circ Cardiovasc Imaging 2023;16(6):e015034. Doi: <a href="https://doi.org/10.1161/circimaging.122.015034">10.1161/circimaging.122.015034</a>.</div>
</div>
<div id="ref-RN39" class="csl-entry" role="listitem">
<div class="csl-left-margin">39. </div><div class="csl-right-inline">Ruddy TD., Wells RG. Measurement of myocardial blood flow with positron emission tomography and single-photon emission computed tomography for diagnosis of cardiac allograft vasculopathy. Circ Cardiovasc Imaging 2023;16(6):e015593. Doi: <a href="https://doi.org/10.1161/circimaging.123.015593">10.1161/circimaging.123.015593</a>.</div>
</div>
<div id="ref-RN40" class="csl-entry" role="listitem">
<div class="csl-left-margin">40. </div><div class="csl-right-inline">Nunoda S., Machida H., Sekikawa A., et al. Evaluation of cardiac allograft vasculopathy by multidetector computed tomography and whole-heart magnetic resonance coronary angiography. Circ J 2010;74(5):946–53. Doi: <a href="https://doi.org/10.1253/circj.cj-09-0800">10.1253/circj.cj-09-0800</a>.</div>
</div>
<div id="ref-RN41" class="csl-entry" role="listitem">
<div class="csl-left-margin">41. </div><div class="csl-right-inline">Bastarrika G., Broncano J., Arraiza M., et al. Systolic prospectively ECG-triggered dual-source CT angiography for evaluation of the coronary arteries in heart transplant recipients. Eur Radiol 2011;21(9):1887–94. Doi: <a href="https://doi.org/10.1007/s00330-011-2126-2">10.1007/s00330-011-2126-2</a>.</div>
</div>
<div id="ref-RN42" class="csl-entry" role="listitem">
<div class="csl-left-margin">42. </div><div class="csl-right-inline">Barthélémy O., Toledano D., Varnous S., et al. Multislice computed tomography to rule out coronary allograft vasculopathy in heart transplant patients. J Heart Lung Transplant 2012;31(12):1262–8. Doi: <a href="https://doi.org/10.1016/j.healun.2012.09.008">10.1016/j.healun.2012.09.008</a>.</div>
</div>
<div id="ref-RN43" class="csl-entry" role="listitem">
<div class="csl-left-margin">43. </div><div class="csl-right-inline">Beitzke D., Berger-Kulemann V., Schöpf V., et al. Dual-source cardiac computed tomography angiography (CCTA) in the follow-up of cardiac transplant: Comparison of image quality and radiation dose using three different imaging protocols. Eur Radiol 2015;25(8):2310–7. Doi: <a href="https://doi.org/10.1007/s00330-015-3650-2">10.1007/s00330-015-3650-2</a>.</div>
</div>
<div id="ref-RN44" class="csl-entry" role="listitem">
<div class="csl-left-margin">44. </div><div class="csl-right-inline">Rohnean A., Houyel L., Sigal-Cinqualbre A., To NT., Elfassy E., Paul JF. Heart transplant patient outcomes: 5-year mean follow-up by coronary computed tomography angiography. Transplantation 2011;91(5):583–8. Doi: <a href="https://doi.org/10.1097/TP.0b013e3182088b96">10.1097/TP.0b013e3182088b96</a>.</div>
</div>
<div id="ref-RN45" class="csl-entry" role="listitem">
<div class="csl-left-margin">45. </div><div class="csl-right-inline">Ferencik M., Brady TJ., Hoffmann U. Computed tomography imaging of cardiac allograft vasculopathy. J Cardiovasc Comput Tomogr 2012;6(4):223–31. Doi: <a href="https://doi.org/10.1016/j.jcct.2011.11.007">10.1016/j.jcct.2011.11.007</a>.</div>
</div>
<div id="ref-RN46" class="csl-entry" role="listitem">
<div class="csl-left-margin">46. </div><div class="csl-right-inline">Khan R., Jang IK. Evaluation of coronary allograft vasculopathy using multi-detector row computed tomography: A systematic review. Eur J Cardiothorac Surg 2012;41(2):415–22. Doi: <a href="https://doi.org/10.1016/j.ejcts.2011.06.033">10.1016/j.ejcts.2011.06.033</a>.</div>
</div>
<div id="ref-RN47" class="csl-entry" role="listitem">
<div class="csl-left-margin">47. </div><div class="csl-right-inline">Wever-Pinzon O., Romero J., Kelesidis I., et al. Coronary computed tomography angiography for the detection of cardiac allograft vasculopathy: A meta-analysis of prospective trials. J Am Coll Cardiol 2014;63(19):1992–2004. Doi: <a href="https://doi.org/10.1016/j.jacc.2014.01.071">10.1016/j.jacc.2014.01.071</a>.</div>
</div>
<div id="ref-RN48" class="csl-entry" role="listitem">
<div class="csl-left-margin">48. </div><div class="csl-right-inline">Nous FMA., Roest S., Dijkman ED van., et al. Clinical implementation of coronary computed tomography angiography for routine detection of cardiac allograft vasculopathy in heart transplant patients. Transpl Int 2021;34(10):1886–94. Doi: <a href="https://doi.org/10.1111/tri.13973">10.1111/tri.13973</a>.</div>
</div>
<div id="ref-RN49" class="csl-entry" role="listitem">
<div class="csl-left-margin">49. </div><div class="csl-right-inline">Ahn Y., Koo HJ., Hyun J., et al. CT coronary angiography and dynamic CT myocardial perfusion for detection of&nbsp;cardiac allograft vasculopathy. JACC Cardiovasc Imaging 2023;16(7):934–47. Doi: <a href="https://doi.org/10.1016/j.jcmg.2022.12.031">10.1016/j.jcmg.2022.12.031</a>.</div>
</div>
<div id="ref-RN50" class="csl-entry" role="listitem">
<div class="csl-left-margin">50. </div><div class="csl-right-inline">Almenar L., Igual B., Martínez-Dolz L., et al. Utility of cardiac magnetic resonance imaging for the diagnosis of heart transplant rejection. Transplant Proc 2003;35(5):1962–4. Doi: <a href="https://doi.org/10.1016/s0041-1345(03)00653-5">10.1016/s0041-1345(03)00653-5</a>.</div>
</div>
<div id="ref-RN51" class="csl-entry" role="listitem">
<div class="csl-left-margin">51. </div><div class="csl-right-inline">Taylor AJ., Vaddadi G., Pfluger H., et al. Diagnostic performance of multisequential cardiac magnetic resonance imaging in acute cardiac allograft rejection. Eur J Heart Fail 2010;12(1):45–51. Doi: <a href="https://doi.org/10.1093/eurjhf/hfp174">10.1093/eurjhf/hfp174</a>.</div>
</div>
<div id="ref-RN52" class="csl-entry" role="listitem">
<div class="csl-left-margin">52. </div><div class="csl-right-inline">Usman AA., Taimen K., Wasielewski M., et al. Cardiac magnetic resonance T2 mapping in the monitoring and follow-up of acute cardiac transplant rejection: A pilot study. Circ Cardiovasc Imaging 2012;5(6):782–90. Doi: <a href="https://doi.org/10.1161/circimaging.111.971101">10.1161/circimaging.111.971101</a>.</div>
</div>
<div id="ref-RN53" class="csl-entry" role="listitem">
<div class="csl-left-margin">53. </div><div class="csl-right-inline">Krieghoff C., Barten MJ., Hildebrand L., et al. Assessment of sub-clinical acute cellular rejection after heart transplantation: Comparison of cardiac magnetic resonance imaging and endomyocardial biopsy. Eur Radiol 2014;24(10):2360–71. Doi: <a href="https://doi.org/10.1007/s00330-014-3246-2">10.1007/s00330-014-3246-2</a>.</div>
</div>
<div id="ref-RN54" class="csl-entry" role="listitem">
<div class="csl-left-margin">54. </div><div class="csl-right-inline">Miller CA., Naish JH., Shaw SM., et al. Multiparametric cardiovascular magnetic resonance surveillance of acute cardiac allograft rejection and characterisation of transplantation-associated myocardial injury: A pilot study. J Cardiovasc Magn Reson 2014;16(1):52. Doi: <a href="https://doi.org/10.1186/s12968-014-0052-6">10.1186/s12968-014-0052-6</a>.</div>
</div>
<div id="ref-RN55" class="csl-entry" role="listitem">
<div class="csl-left-margin">55. </div><div class="csl-right-inline">Butler CR., Savu A., Bakal JA., et al. Correlation of cardiovascular magnetic resonance imaging findings and endomyocardial biopsy results in patients undergoing screening for heart transplant rejection. J Heart Lung Transplant 2015;34(5):643–50. Doi: <a href="https://doi.org/10.1016/j.healun.2014.12.020">10.1016/j.healun.2014.12.020</a>.</div>
</div>
<div id="ref-RN56" class="csl-entry" role="listitem">
<div class="csl-left-margin">56. </div><div class="csl-right-inline">Lu W., Zheng J., Pan XD., et al. Diagnostic performance of cardiac magnetic resonance for the detection of acute cardiac allograft rejection: A systematic review and meta-analysis. J Thorac Dis 2015;7(3):252–63. Doi: <a href="https://doi.org/10.3978/j.issn.2072-1439.2015.01.27">10.3978/j.issn.2072-1439.2015.01.27</a>.</div>
</div>
<div id="ref-RN57" class="csl-entry" role="listitem">
<div class="csl-left-margin">57. </div><div class="csl-right-inline">Vermes E., Pantaléon C., Auvet A., et al. Cardiovascular magnetic resonance in heart transplant patients: Diagnostic value of quantitative tissue markers: T2 mapping and extracellular volume fraction, for acute rejection diagnosis. J Cardiovasc Magn Reson 2018;20(1):59. Doi: <a href="https://doi.org/10.1186/s12968-018-0480-9">10.1186/s12968-018-0480-9</a>.</div>
</div>
<div id="ref-RN58" class="csl-entry" role="listitem">
<div class="csl-left-margin">58. </div><div class="csl-right-inline">Dolan RS., Rahsepar AA., Blaisdell J., et al. Multiparametric cardiac magnetic resonance imaging can detect acute&nbsp;cardiac allograft rejection after&nbsp;heart transplantation. JACC Cardiovasc Imaging 2019;12(8 Pt 2):1632–41. Doi: <a href="https://doi.org/10.1016/j.jcmg.2019.01.026">10.1016/j.jcmg.2019.01.026</a>.</div>
</div>
<div id="ref-RN59" class="csl-entry" role="listitem">
<div class="csl-left-margin">59. </div><div class="csl-right-inline">Miller RJH., Thomson L., Levine R., et al. Quantitative myocardial tissue characterization by cardiac magnetic resonance in heart transplant patients with suspected cardiac rejection. Clin Transplant 2019;33(10):e13704. Doi: <a href="https://doi.org/10.1111/ctr.13704">10.1111/ctr.13704</a>.</div>
</div>
<div id="ref-RN60" class="csl-entry" role="listitem">
<div class="csl-left-margin">60. </div><div class="csl-right-inline">Sethi N., Doshi A., Doshi T., et al. Quantitative cardiac magnetic resonance T2 imaging offers ability to non-invasively predict acute allograft rejection in children. Cardiol Young 2020;30(6):852–9. Doi: <a href="https://doi.org/10.1017/s104795112000116x">10.1017/s104795112000116x</a>.</div>
</div>
<div id="ref-RN61" class="csl-entry" role="listitem">
<div class="csl-left-margin">61. </div><div class="csl-right-inline">Han D., Miller RJH., Otaki Y., et al. Diagnostic accuracy of cardiovascular&nbsp;magnetic resonance for cardiac transplant rejection: A meta-analysis. JACC Cardiovasc Imaging 2021;14(12):2337–49. Doi: <a href="https://doi.org/10.1016/j.jcmg.2021.05.008">10.1016/j.jcmg.2021.05.008</a>.</div>
</div>
<div id="ref-RN62" class="csl-entry" role="listitem">
<div class="csl-left-margin">62. </div><div class="csl-right-inline">Anthony C., Imran M., Pouliopoulos J., et al. Cardiovascular magnetic resonance for rejection surveillance after cardiac transplantation. Circulation 2022;145(25):1811–24. Doi: <a href="https://doi.org/10.1161/circulationaha.121.057006">10.1161/circulationaha.121.057006</a>.</div>
</div>
<div id="ref-RN63" class="csl-entry" role="listitem">
<div class="csl-left-margin">63. </div><div class="csl-right-inline">Korosoglou G., Osman NF., Dengler TJ., et al. Strain-encoded cardiac magnetic resonance for the evaluation of chronic allograft vasculopathy in transplant recipients. Am J Transplant 2009;9(11):2587–96. Doi: <a href="https://doi.org/10.1111/j.1600-6143.2009.02769.x">10.1111/j.1600-6143.2009.02769.x</a>.</div>
</div>
<div id="ref-RN64" class="csl-entry" role="listitem">
<div class="csl-left-margin">64. </div><div class="csl-right-inline">Colvin-Adams M., Petros S., Raveendran G., Missov E., Medina E., Wilson R. Qualitative perfusion cardiac magnetic resonance imaging lacks sensitivity in detecting cardiac allograft vasculopathy. Cardiol Res 2011;2(6):282–7. Doi: <a href="https://doi.org/10.4021/cr105w">10.4021/cr105w</a>.</div>
</div>
<div id="ref-RN65" class="csl-entry" role="listitem">
<div class="csl-left-margin">65. </div><div class="csl-right-inline">Machida H., Nunoda S., Okajima K., et al. Magnetic resonance assessment of left ventricular diastolic dysfunction for detecting cardiac allograft vasculopathy in recipients of heart transplants. Int J Cardiovasc Imaging 2012;28(3):555–62. Doi: <a href="https://doi.org/10.1007/s10554-011-9853-y">10.1007/s10554-011-9853-y</a>.</div>
</div>
<div id="ref-RN66" class="csl-entry" role="listitem">
<div class="csl-left-margin">66. </div><div class="csl-right-inline">Hussain T., Fenton M., Peel SA., et al. Detection and grading of coronary allograft vasculopathy in children with contrast-enhanced magnetic resonance imaging of the coronary vessel wall. Circ Cardiovasc Imaging 2013;6(1):91–8. Doi: <a href="https://doi.org/10.1161/circimaging.112.975797">10.1161/circimaging.112.975797</a>.</div>
</div>
<div id="ref-RN67" class="csl-entry" role="listitem">
<div class="csl-left-margin">67. </div><div class="csl-right-inline">Machida H., Nunoda S., Shitakura K., et al. Usefulness of left ventricular diastolic function assessed by magnetic resonance imaging over invasive coronary flow reserve measurement for detecting cardiac allograft vasculopathy in heart transplant recipients. Int J Cardiovasc Imaging 2013;29(1):151–7. Doi: <a href="https://doi.org/10.1007/s10554-012-0070-0">10.1007/s10554-012-0070-0</a>.</div>
</div>
<div id="ref-RN68" class="csl-entry" role="listitem">
<div class="csl-left-margin">68. </div><div class="csl-right-inline">Braggion-Santos MF., Lossnitzer D., Buss S., et al. Late gadolinium enhancement assessed by cardiac magnetic resonance imaging in heart transplant recipients with different stages of cardiac allograft vasculopathy. Eur Heart J Cardiovasc Imaging 2014;15(10):1125–32. Doi: <a href="https://doi.org/10.1093/ehjci/jeu090">10.1093/ehjci/jeu090</a>.</div>
</div>
<div id="ref-RN69" class="csl-entry" role="listitem">
<div class="csl-left-margin">69. </div><div class="csl-right-inline">Miller CA., Sarma J., Naish JH., et al. Multiparametric cardiovascular magnetic resonance assessment of cardiac allograft vasculopathy. J Am Coll Cardiol 2014;63(8):799–808. Doi: <a href="https://doi.org/10.1016/j.jacc.2013.07.119">10.1016/j.jacc.2013.07.119</a>.</div>
</div>
<div id="ref-RN70" class="csl-entry" role="listitem">
<div class="csl-left-margin">70. </div><div class="csl-right-inline">Mirelis JG., García-Pavía P., Cavero MA., et al. Magnetic resonance for noninvasive detection of microcirculatory disease associated with allograft vasculopathy: Intracoronary measurement validation. Rev Esp Cardiol (Engl Ed) 2015;68(7):571–8. Doi: <a href="https://doi.org/10.1016/j.rec.2014.07.030">10.1016/j.rec.2014.07.030</a>.</div>
</div>
<div id="ref-RN71" class="csl-entry" role="listitem">
<div class="csl-left-margin">71. </div><div class="csl-right-inline">Chih S., Ross HJ., Alba AC., Fan CS., Manlhiot C., Crean AM. Perfusion cardiac magnetic resonance imaging as a rule-out test for cardiac allograft vasculopathy. Am J Transplant 2016;16(10):3007–15. Doi: <a href="https://doi.org/10.1111/ajt.13839">10.1111/ajt.13839</a>.</div>
</div>
<div id="ref-RN72" class="csl-entry" role="listitem">
<div class="csl-left-margin">72. </div><div class="csl-right-inline">Erbel C., Mukhammadaminova N., Gleissner CA., et al. Myocardial perfusion reserve and strain-encoded CMR for evaluation of cardiac allograft microvasculopathy. JACC Cardiovasc Imaging 2016;9(3):255–66. Doi: <a href="https://doi.org/10.1016/j.jcmg.2015.10.012">10.1016/j.jcmg.2015.10.012</a>.</div>
</div>
<div id="ref-RN73" class="csl-entry" role="listitem">
<div class="csl-left-margin">73. </div><div class="csl-right-inline">DeSa TB., Abbasi MA., Blaisdell JA., et al. Semi-quantitative myocardial perfusion MRI in heart transplant recipients at rest: Repeatability in healthy controls and assessment of cardiac allograft vasculopathy. Clin Imaging 2020;61:62–8. Doi: <a href="https://doi.org/10.1016/j.clinimag.2019.12.011">10.1016/j.clinimag.2019.12.011</a>.</div>
</div>
<div id="ref-RN74" class="csl-entry" role="listitem">
<div class="csl-left-margin">74. </div><div class="csl-right-inline">Abbasi MA., Blake AM., Sarnari R., et al. Multiparametric cardiac magnetic resonance imaging detects altered myocardial tissue and function in heart transplantation recipients monitored for cardiac allograft vasculopathy. J Cardiovasc Imaging 2022;30(4):263–75. Doi: <a href="https://doi.org/10.4250/jcvi.2022.0003">10.4250/jcvi.2022.0003</a>.</div>
</div>
<div id="ref-RN84" class="csl-entry" role="listitem">
<div class="csl-left-margin">75. </div><div class="csl-right-inline">Ojha V., Ganga KP., Mani A., et al. Detection of cardiac allograft vasculopathy on dual source computed tomography in heart transplant recipients: Comparison with invasive coronary angiography. Br J Radiol 2022;95(1134):20211237. Doi: <a href="https://doi.org/10.1259/bjr.20211237">10.1259/bjr.20211237</a>.</div>
</div>
<div id="ref-RN85" class="csl-entry" role="listitem">
<div class="csl-left-margin">76. </div><div class="csl-right-inline">Einstein AJ., Sanz J., Dellegrottaglie S., et al. Radiation dose and cancer risk estimates in 16-slice computed tomography coronary angiography. J Nucl Cardiol 2008;15(2):232–40. Doi: <a href="https://doi.org/10.1016/j.nuclcard.2007.09.028">10.1016/j.nuclcard.2007.09.028</a>.</div>
</div>
<div id="ref-RN86" class="csl-entry" role="listitem">
<div class="csl-left-margin">77. </div><div class="csl-right-inline">Einstein AJ., Henzlova MJ., Rajagopalan S. Estimating risk of cancer associated with radiation exposure from 64-slice computed tomography coronary angiography. JAMA 2007;298(3):317–23. Doi: <a href="https://doi.org/10.1001/jama.298.3.317">10.1001/jama.298.3.317</a>.</div>
</div>
<div id="ref-RN87" class="csl-entry" role="listitem">
<div class="csl-left-margin">78. </div><div class="csl-right-inline">Olymbios M., Kwiecinski J., Berman DS., Kobashigawa JA. Imaging in heart transplant patients. JACC Cardiovasc Imaging 2018;11(10):1514–30. Doi: <a href="https://doi.org/10.1016/j.jcmg.2018.06.019">10.1016/j.jcmg.2018.06.019</a>.</div>
</div>
<div id="ref-RN88" class="csl-entry" role="listitem">
<div class="csl-left-margin">79. </div><div class="csl-right-inline">Kazmirczak F., Nijjar PS., Zhang L., et al. Safety and prognostic value of regadenoson stress cardiovascular magnetic resonance imaging in heart transplant recipients. J Cardiovasc Magn Reson 2019;21(1):9. Doi: <a href="https://doi.org/10.1186/s12968-018-0515-2">10.1186/s12968-018-0515-2</a>.</div>
</div>
<div id="ref-RN89" class="csl-entry" role="listitem">
<div class="csl-left-margin">80. </div><div class="csl-right-inline">Patel SG., Husain N., Rigsby CK., Robinson JD. Safety and efficacy of regadenoson for pediatric stress perfusion cardiac MRI with quantification of myocardial blood flow. Children (Basel) 2022;9(9). Doi: <a href="https://doi.org/10.3390/children9091332">10.3390/children9091332</a>.</div>
</div>
<div id="ref-RN90" class="csl-entry" role="listitem">
<div class="csl-left-margin">81. </div><div class="csl-right-inline">Ko K-Y., Ko C-L., Lee C-M., et al. Myocardial flow assessment after heart transplantation using dynamic cadmium-zinc-telluride single-photon emission computed tomography with 201Tl and 99mTc tracers and validated by 13N-NH3 positron emission tomography. Circulation: Cardiovascular Imaging 2023;16(6):e015034. Doi: <a href="https://doi.org/10.1161/CIRCIMAGING.122.015034">10.1161/CIRCIMAGING.122.015034</a>.</div>
</div>
<div id="ref-RN91" class="csl-entry" role="listitem">
<div class="csl-left-margin">82. </div><div class="csl-right-inline">Jiménez-Jaso JM., Ezponda A., Sáenz-Diez JM., Caballeros M., Rábago G., Bastarrika G. Cardiac magnetic resonance imaging myocardial perfusion reserve index in heart transplant patients. Radiologia (Engl Ed) 2020;62(6):493–501. Doi: <a href="https://doi.org/10.1016/j.rx.2020.04.004">10.1016/j.rx.2020.04.004</a>.</div>
</div>
<div id="ref-RN92" class="csl-entry" role="listitem">
<div class="csl-left-margin">83. </div><div class="csl-right-inline">Hofmann NP., Steuer C., Voss A., et al. Comprehensive bio-imaging using myocardial perfusion reserve index during cardiac magnetic resonance imaging and high-sensitive troponin t for the prediction of outcomes in heart transplant recipients. Am J Transplant 2014;14(11):2607–16. Doi: <a href="https://doi.org/10.1111/ajt.12924">10.1111/ajt.12924</a>.</div>
</div>
<div id="ref-RN94" class="csl-entry" role="listitem">
<div class="csl-left-margin">84. </div><div class="csl-right-inline">Kontopantelis E., Doran T., Springate DA., Buchan I., Reeves D. Regression based quasi-experimental approach when randomisation is not an option: Interrupted time series analysis. Bmj 2015;350:h2750. Doi: <a href="https://doi.org/10.1136/bmj.h2750">10.1136/bmj.h2750</a>.</div>
</div>
<div id="ref-RN95" class="csl-entry" role="listitem">
<div class="csl-left-margin">85. </div><div class="csl-right-inline">Picano E. Economic, ethical, and environmental sustainability of cardiac imaging. Eur Heart J 2023;44(45):4748–51. Doi: <a href="https://doi.org/10.1093/eurheartj/ehac716">10.1093/eurheartj/ehac716</a>.</div>
</div>
<div id="ref-RN96" class="csl-entry" role="listitem">
<div class="csl-left-margin">86. </div><div class="csl-right-inline">Czernin J., Müller P., Chan S., et al. Influence of age and hemodynamics on myocardial blood flow and flow reserve. Circulation 1993;88(1):62–9. Doi: <a href="https://doi.org/10.1161/01.cir.88.1.62">10.1161/01.cir.88.1.62</a>.</div>
</div>
<div id="ref-RN76" class="csl-entry" role="listitem">
<div class="csl-left-margin">87. </div><div class="csl-right-inline">Muehling OM., Wilke NM., Panse P., et al. Reduced myocardial perfusion reserve and transmural perfusion gradient in heart transplant arteriopathy assessed by magnetic resonance imaging. J Am Coll Cardiol 2003;42(6):1054–60. Doi: <a href="https://doi.org/10.1016/s0735-1097(03)00924-0">10.1016/s0735-1097(03)00924-0</a>.</div>
</div>
<div id="ref-RN97" class="csl-entry" role="listitem">
<div class="csl-left-margin">88. </div><div class="csl-right-inline">Grupper A., Gewirtz H., Kushwaha S. Reinnervation post-heart transplantation. Eur Heart J 2018;39(20):1799–806. Doi: <a href="https://doi.org/10.1093/eurheartj/ehw604">10.1093/eurheartj/ehw604</a>.</div>
</div>
</div>
</section>
<section id="appendix" class="level2">
<h2 class="anchored" data-anchor-id="appendix">Appendix</h2>
<section id="statistical-software-and-packages" class="level3">
<h3 class="anchored" data-anchor-id="statistical-software-and-packages">Statistical software and packages</h3>
<p>The thesis was compiled with R and Quarto in VS Code. R packages utilized included ggplot2, ggstatsplot, pROC, dca, dplyr, tidyr, knitr, survival, and gtsummary.</p>
</section>
<section id="supplemental-results" class="level3">
<h3 class="anchored" data-anchor-id="supplemental-results">Supplemental results</h3>
<section id="relationship-between-mbf-and-the-rate-pressure-product" class="level4">
<h4 class="anchored" data-anchor-id="relationship-between-mbf-and-the-rate-pressure-product">Relationship between MBF and the rate-pressure product</h4>
<p>Adjustment of CMR-derived MBF and MPR to the rate-pressure product (RPP) is a matter of ongoing debate. The rate-pressure product is the double product of heart rate and systolic blood pressure, with both parameters typically measured at rest. Since its first introduction in 1993, the RPP was utilized for adjustment of the rest MBF <span class="citation" data-cites="RN96">(<a href="#ref-RN96" role="doc-biblioref">86</a>)</span> to account for differences in baseline haemodynamic conditions across patients; it was in fact observed that the significant correlation between RPP and MBF would lose strength and significance when both parameters were measured during vasodilator-induced stress. For this reason, stress MBF was typically not normalized by the RPP. This was also the case in heart transplant recipients <span class="citation" data-cites="RN76">(<a href="#ref-RN76" role="doc-biblioref">87</a>)</span>. We tested for the existence of a correlation between RPP and MBF at both rest and stress in the present cohort. As exemplified by Supplemental Figures 3 and 4, a stronger, significant correlation was identified between stress RPP and stress MBF, than it was found with both parameters at rest. One reason why the rationale of adjusting only the rest MBF might not entirely apply to heart transplant recipients is that these patients, besides presenting with different baseline haemodynamic conditions, also show diverse haemodynamic response to pharmacological vasodilation, possibly in keeping with the varying degree of graft reinnervation and thus, autonomic control over the implanted heart <span class="citation" data-cites="RN97">(<a href="#ref-RN97" role="doc-biblioref">88</a>)</span>. In their study of heart transplant recipients undergoing stress perfusion CMR published 20 years ago <span class="citation" data-cites="RN76">(<a href="#ref-RN76" role="doc-biblioref">87</a>)</span>, Muehling and colleagues found significant correlation between rest MBF and rest RPP, but not between these parameters at stress (personal correspondence, courtesy of Peter Kellman and Michael Jerosch-Herold). They also reported that, in contrast with healthy controls, the RPP in heart transplant recipients was reduced upon vasodilation with adenosine, rather than increased. This was not the case in this cohort. In fact, we show that the RPP modestly increased between rest and stress (10,764±2,413 to 11,309±2,627, p = 0.06 for difference; Supplemental Figure 5). Importantly, our cohort differed significantly from the one investigated by Muehling et al., since they enrolled patients between 2 and 14 years from transplantation, while in our cohort, we reported on patients with graft age ranging from &lt; 1 to &gt; 30 years, with the large majority of patients at &gt; 10 years from graft implantation. We investigated the observed heterogeneity in RPP change between rest and stress. Age and time from transplantation were not significantly associated with change in RPP (p = 0.45 and 0.92, respectively); this plausibly excludes the hypothesis that the haemodynamic response to adenosine after transplantation is explained simply by reinnervation, which remains limited and incomplete long-term after the procedure <span class="citation" data-cites="RN97">(<a href="#ref-RN97" role="doc-biblioref">88</a>)</span>. Instead, male sex and positivity to DSA were significant predictors of a positive change in RPP (Supplemental Figures 6–8). Finally, stress MBF index, but not MPR index or rest MBF index, was inversely correlated with graft age, defined as the time between graft implantation and CMR (Supplemental Figure 9). The pathophysiological foundations and possible prognostic implications of such «pseudonormalization» of the RPP response on the lifetime trajectory of cardiac grafts are unknown.</p>
</section>
<section id="stress-mbf-index" class="level4">
<h4 class="anchored" data-anchor-id="stress-mbf-index">Stress MBF index</h4>
<p>Given our finding of a significant correlation between RPP and MBF at stress, we conducted exploratory analyses on the diagnostic yield of the stress MBF adjusted to the stress rate-pressure product. We found comparable diagnostic and prognostic yield to the more «conventional» MPR index. Stress MBF index was found to significantly discriminate patients with moderate to severe CAV from those without significant coronary disease (p = 0.014). At a diagnostic threshold of 2.2, stress MBF index had a sensitivity of 92.9% and a specificity of 55.3%, and was also prognostic (HR 0.11, 95%CI 0.02-0.54, p = 0.007).</p>
</section>
<section id="stress-mbf-index-and-positivity-to-donor-specific-antibodies" class="level4">
<h4 class="anchored" data-anchor-id="stress-mbf-index-and-positivity-to-donor-specific-antibodies">Stress MBF index and positivity to donor-specific antibodies</h4>
<p>The low specificity observed with stress MBF index indicated a high rate of false positive tests, or patients with reduced stress MBF index who had no significant CAV on the index angiography. Patients with a false positive result were similar in baseline characteristics to patients with other test results, but they had a significantly higher prevalence of donor-specific antibodies (DSA) (p = 0.029) on blood samples tested within 36 (11-99) days from the CMR study. We separately evaluated the diagnostic accuracy in patients with a negative DSA test, and found no difference in sensitivity (90.0% vs 92.9%) and a nominal increase in specificity (72.7% vs 55.3%), with an overall improvement in AUC from 0.69 to 0.80.</p>
</section>
</section>
<section id="supplemental-tables" class="level3">
<h3 class="anchored" data-anchor-id="supplemental-tables">Supplemental tables</h3>
</section>
<section id="supplemental-figures" class="level3">
<h3 class="anchored" data-anchor-id="supplemental-figures">Supplemental figures</h3>
</section>
</section>
<section id="list-of-publications" class="level2">
<h2 class="anchored" data-anchor-id="list-of-publications">List of publications</h2>
<p>Please find my <a href="./publist.html">list of publications</a>.</p>
</section>
<section id="license" class="level2">
<h2 class="anchored" data-anchor-id="license">License</h2>
<p>The content of this thesis is licensed under a Creative Commons License, Attribution - Noncommercial - NoDerivative Works 4.0 International: see www.creativecommons.org. The text may be reproduced for non-commercial purposes, provided that credit is given to the original author. I hereby declare that the contents and organisation of this dissertation are the product of my own original work and do not compromise in any way the rights of third parties, including those relating to the security of personal data.</p>


</section>
</section>

</main> <!-- /main -->
<script id="quarto-html-after-body" type="application/javascript">
window.document.addEventListener("DOMContentLoaded", function (event) {
  const toggleBodyColorMode = (bsSheetEl) => {
    const mode = bsSheetEl.getAttribute("data-mode");
    const bodyEl = window.document.querySelector("body");
    if (mode === "dark") {
      bodyEl.classList.add("quarto-dark");
      bodyEl.classList.remove("quarto-light");
    } else {
      bodyEl.classList.add("quarto-light");
      bodyEl.classList.remove("quarto-dark");
    }
  }
  const toggleBodyColorPrimary = () => {
    const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
    if (bsSheetEl) {
      toggleBodyColorMode(bsSheetEl);
    }
  }
  toggleBodyColorPrimary();  
  const icon = "";
  const anchorJS = new window.AnchorJS();
  anchorJS.options = {
    placement: 'right',
    icon: icon
  };
  anchorJS.add('.anchored');
  const isCodeAnnotation = (el) => {
    for (const clz of el.classList) {
      if (clz.startsWith('code-annotation-')) {                     
        return true;
      }
    }
    return false;
  }
  const clipboard = new window.ClipboardJS('.code-copy-button', {
    text: function(trigger) {
      const codeEl = trigger.previousElementSibling.cloneNode(true);
      for (const childEl of codeEl.children) {
        if (isCodeAnnotation(childEl)) {
          childEl.remove();
        }
      }
      return codeEl.innerText;
    }
  });
  clipboard.on('success', function(e) {
    // button target
    const button = e.trigger;
    // don't keep focus
    button.blur();
    // flash "checked"
    button.classList.add('code-copy-button-checked');
    var currentTitle = button.getAttribute("title");
    button.setAttribute("title", "Copied!");
    let tooltip;
    if (window.bootstrap) {
      button.setAttribute("data-bs-toggle", "tooltip");
      button.setAttribute("data-bs-placement", "left");
      button.setAttribute("data-bs-title", "Copied!");
      tooltip = new bootstrap.Tooltip(button, 
        { trigger: "manual", 
          customClass: "code-copy-button-tooltip",
          offset: [0, -8]});
      tooltip.show();    
    }
    setTimeout(function() {
      if (tooltip) {
        tooltip.hide();
        button.removeAttribute("data-bs-title");
        button.removeAttribute("data-bs-toggle");
        button.removeAttribute("data-bs-placement");
      }
      button.setAttribute("title", currentTitle);
      button.classList.remove('code-copy-button-checked');
    }, 1000);
    // clear code selection
    e.clearSelection();
  });
  function tippyHover(el, contentFn, onTriggerFn, onUntriggerFn) {
    const config = {
      allowHTML: true,
      maxWidth: 500,
      delay: 100,
      arrow: false,
      appendTo: function(el) {
          return el.parentElement;
      },
      interactive: true,
      interactiveBorder: 10,
      theme: 'quarto',
      placement: 'bottom-start',
    };
    if (contentFn) {
      config.content = contentFn;
    }
    if (onTriggerFn) {
      config.onTrigger = onTriggerFn;
    }
    if (onUntriggerFn) {
      config.onUntrigger = onUntriggerFn;
    }
    window.tippy(el, config); 
  }
  const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
  for (var i=0; i<noterefs.length; i++) {
    const ref = noterefs[i];
    tippyHover(ref, function() {
      // use id or data attribute instead here
      let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
      try { href = new URL(href).hash; } catch {}
      const id = href.replace(/^#\/?/, "");
      const note = window.document.getElementById(id);
      return note.innerHTML;
    });
  }
  const xrefs = window.document.querySelectorAll('a.quarto-xref');
  const processXRef = (id, note) => {
    // Strip column container classes
    const stripColumnClz = (el) => {
      el.classList.remove("page-full", "page-columns");
      if (el.children) {
        for (const child of el.children) {
          stripColumnClz(child);
        }
      }
    }
    stripColumnClz(note)
    if (id === null || id.startsWith('sec-')) {
      // Special case sections, only their first couple elements
      const container = document.createElement("div");
      if (note.children && note.children.length > 2) {
        container.appendChild(note.children[0].cloneNode(true));
        for (let i = 1; i < note.children.length; i++) {
          const child = note.children[i];
          if (child.tagName === "P" && child.innerText === "") {
            continue;
          } else {
            container.appendChild(child.cloneNode(true));
            break;
          }
        }
        if (window.Quarto?.typesetMath) {
          window.Quarto.typesetMath(container);
        }
        return container.innerHTML
      } else {
        if (window.Quarto?.typesetMath) {
          window.Quarto.typesetMath(note);
        }
        return note.innerHTML;
      }
    } else {
      // Remove any anchor links if they are present
      const anchorLink = note.querySelector('a.anchorjs-link');
      if (anchorLink) {
        anchorLink.remove();
      }
      if (window.Quarto?.typesetMath) {
        window.Quarto.typesetMath(note);
      }
      // TODO in 1.5, we should make sure this works without a callout special case
      if (note.classList.contains("callout")) {
        return note.outerHTML;
      } else {
        return note.innerHTML;
      }
    }
  }
  for (var i=0; i<xrefs.length; i++) {
    const xref = xrefs[i];
    tippyHover(xref, undefined, function(instance) {
      instance.disable();
      let url = xref.getAttribute('href');
      let hash = undefined; 
      if (url.startsWith('#')) {
        hash = url;
      } else {
        try { hash = new URL(url).hash; } catch {}
      }
      if (hash) {
        const id = hash.replace(/^#\/?/, "");
        const note = window.document.getElementById(id);
        if (note !== null) {
          try {
            const html = processXRef(id, note.cloneNode(true));
            instance.setContent(html);
          } finally {
            instance.enable();
            instance.show();
          }
        } else {
          // See if we can fetch this
          fetch(url.split('#')[0])
          .then(res => res.text())
          .then(html => {
            const parser = new DOMParser();
            const htmlDoc = parser.parseFromString(html, "text/html");
            const note = htmlDoc.getElementById(id);
            if (note !== null) {
              const html = processXRef(id, note);
              instance.setContent(html);
            } 
          }).finally(() => {
            instance.enable();
            instance.show();
          });
        }
      } else {
        // See if we can fetch a full url (with no hash to target)
        // This is a special case and we should probably do some content thinning / targeting
        fetch(url)
        .then(res => res.text())
        .then(html => {
          const parser = new DOMParser();
          const htmlDoc = parser.parseFromString(html, "text/html");
          const note = htmlDoc.querySelector('main.content');
          if (note !== null) {
            // This should only happen for chapter cross references
            // (since there is no id in the URL)
            // remove the first header
            if (note.children.length > 0 && note.children[0].tagName === "HEADER") {
              note.children[0].remove();
            }
            const html = processXRef(null, note);
            instance.setContent(html);
          } 
        }).finally(() => {
          instance.enable();
          instance.show();
        });
      }
    }, function(instance) {
    });
  }
      let selectedAnnoteEl;
      const selectorForAnnotation = ( cell, annotation) => {
        let cellAttr = 'data-code-cell="' + cell + '"';
        let lineAttr = 'data-code-annotation="' +  annotation + '"';
        const selector = 'span[' + cellAttr + '][' + lineAttr + ']';
        return selector;
      }
      const selectCodeLines = (annoteEl) => {
        const doc = window.document;
        const targetCell = annoteEl.getAttribute("data-target-cell");
        const targetAnnotation = annoteEl.getAttribute("data-target-annotation");
        const annoteSpan = window.document.querySelector(selectorForAnnotation(targetCell, targetAnnotation));
        const lines = annoteSpan.getAttribute("data-code-lines").split(",");
        const lineIds = lines.map((line) => {
          return targetCell + "-" + line;
        })
        let top = null;
        let height = null;
        let parent = null;
        if (lineIds.length > 0) {
            //compute the position of the single el (top and bottom and make a div)
            const el = window.document.getElementById(lineIds[0]);
            top = el.offsetTop;
            height = el.offsetHeight;
            parent = el.parentElement.parentElement;
          if (lineIds.length > 1) {
            const lastEl = window.document.getElementById(lineIds[lineIds.length - 1]);
            const bottom = lastEl.offsetTop + lastEl.offsetHeight;
            height = bottom - top;
          }
          if (top !== null && height !== null && parent !== null) {
            // cook up a div (if necessary) and position it 
            let div = window.document.getElementById("code-annotation-line-highlight");
            if (div === null) {
              div = window.document.createElement("div");
              div.setAttribute("id", "code-annotation-line-highlight");
              div.style.position = 'absolute';
              parent.appendChild(div);
            }
            div.style.top = top - 2 + "px";
            div.style.height = height + 4 + "px";
            div.style.left = 0;
            let gutterDiv = window.document.getElementById("code-annotation-line-highlight-gutter");
            if (gutterDiv === null) {
              gutterDiv = window.document.createElement("div");
              gutterDiv.setAttribute("id", "code-annotation-line-highlight-gutter");
              gutterDiv.style.position = 'absolute';
              const codeCell = window.document.getElementById(targetCell);
              const gutter = codeCell.querySelector('.code-annotation-gutter');
              gutter.appendChild(gutterDiv);
            }
            gutterDiv.style.top = top - 2 + "px";
            gutterDiv.style.height = height + 4 + "px";
          }
          selectedAnnoteEl = annoteEl;
        }
      };
      const unselectCodeLines = () => {
        const elementsIds = ["code-annotation-line-highlight", "code-annotation-line-highlight-gutter"];
        elementsIds.forEach((elId) => {
          const div = window.document.getElementById(elId);
          if (div) {
            div.remove();
          }
        });
        selectedAnnoteEl = undefined;
      };
        // Handle positioning of the toggle
    window.addEventListener(
      "resize",
      throttle(() => {
        elRect = undefined;
        if (selectedAnnoteEl) {
          selectCodeLines(selectedAnnoteEl);
        }
      }, 10)
    );
    function throttle(fn, ms) {
    let throttle = false;
    let timer;
      return (...args) => {
        if(!throttle) { // first call gets through
            fn.apply(this, args);
            throttle = true;
        } else { // all the others get throttled
            if(timer) clearTimeout(timer); // cancel #2
            timer = setTimeout(() => {
              fn.apply(this, args);
              timer = throttle = false;
            }, ms);
        }
      };
    }
      // Attach click handler to the DT
      const annoteDls = window.document.querySelectorAll('dt[data-target-cell]');
      for (const annoteDlNode of annoteDls) {
        annoteDlNode.addEventListener('click', (event) => {
          const clickedEl = event.target;
          if (clickedEl !== selectedAnnoteEl) {
            unselectCodeLines();
            const activeEl = window.document.querySelector('dt[data-target-cell].code-annotation-active');
            if (activeEl) {
              activeEl.classList.remove('code-annotation-active');
            }
            selectCodeLines(clickedEl);
            clickedEl.classList.add('code-annotation-active');
          } else {
            // Unselect the line
            unselectCodeLines();
            clickedEl.classList.remove('code-annotation-active');
          }
        });
      }
  const findCites = (el) => {
    const parentEl = el.parentElement;
    if (parentEl) {
      const cites = parentEl.dataset.cites;
      if (cites) {
        return {
          el,
          cites: cites.split(' ')
        };
      } else {
        return findCites(el.parentElement)
      }
    } else {
      return undefined;
    }
  };
  var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
  for (var i=0; i<bibliorefs.length; i++) {
    const ref = bibliorefs[i];
    const citeInfo = findCites(ref);
    if (citeInfo) {
      tippyHover(citeInfo.el, function() {
        var popup = window.document.createElement('div');
        citeInfo.cites.forEach(function(cite) {
          var citeDiv = window.document.createElement('div');
          citeDiv.classList.add('hanging-indent');
          citeDiv.classList.add('csl-entry');
          var biblioDiv = window.document.getElementById('ref-' + cite);
          if (biblioDiv) {
            citeDiv.innerHTML = biblioDiv.innerHTML;
          }
          popup.appendChild(citeDiv);
        });
        return popup.innerHTML;
      });
    }
  }
});
</script>
</div> <!-- /content -->
<footer class="footer">
  <div class="nav-footer">
    <div class="nav-footer-left">
      &nbsp;
    </div>   
    <div class="nav-footer-center">
<p>Giandomenico Bisaccia 2024</p>
</div>
    <div class="nav-footer-right">
      &nbsp;
    </div>
  </div>
</footer>




</body></html>